camptothecin has been researched along with Cancer of Stomach in 561 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (0.18) | 18.7374 |
1990's | 18 (3.21) | 18.2507 |
2000's | 258 (45.99) | 29.6817 |
2010's | 261 (46.52) | 24.3611 |
2020's | 23 (4.10) | 2.80 |
Authors | Studies |
---|---|
Deng, J; Lei, F; Li, J; Liang, Z; Shi, T; Wang, Y; Wang, Z; Yang, X; Zhang, H | 1 |
Ishii, T; Shitara, K | 1 |
Ajani, JA; Rogers, JE; Trail, A; Wang, X | 1 |
Fujita, Y; Muro, K; Ogata, T | 1 |
Heltzel, C; Kalmuk, J; Lockhart, AC; Rinder, D | 1 |
Guo, W; Ma, X; Sun, J; Wang, Z; Xu, H; Zhang, H; Zhang, T; Zhong, X | 1 |
Cardillo, TM; Donnell, J; Govindan, SV; Hofsess, S; Kopp, A; Thurber, GM | 1 |
Bai, L; Chen, L; Guo, C; Guo, D; Jiang, P; Jiang, Z; Shi, J; Tong, R; Xu, Z; Yu, D; Zhu, Y | 1 |
Bi, F; Chen, H; Li, Q; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K | 1 |
Chen, J; He, GM; Su, XQ; Xian, GY; Yao, F; Yu, LL | 1 |
Ajani, JA; Blum Murphy, M; Palmer, M; Rogers, JE; Trail, A; Xiao, L | 1 |
Bang, YJ; Chung, HC; Iwasa, S; Kamio, T; Kawaguchi, Y; Kawakami, H; Kojima, A; Lee, J; Ryu, MH; Saito, K; Sakai, D; Shitara, K; Sugihara, M; Sugimoto, N; Yabusaki, H; Yamaguchi, K | 1 |
Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
Marsoni, S; Sartore-Bianchi, A; Siena, S | 1 |
Aparicio, T; Bibeau, F; Bouché, O; Chibaudel, B; Desrame, J; Evrard, C; Fiore, FD; Gonzalez, D; Guimbaud, R; Hajbi, FE; Kim, S; Laurent-Puig, P; Lecomte, T; Lepage, C; Lièvre, A; Louvet, C; Malicot, KL; Pierre, S; Sokol, H; Tougeron, D; Zaanan, A | 1 |
Aoki, M; Boku, N; Iwasa, S | 1 |
Ando, K; Bharti, A; Fujimoto, Y; Hisamatsu, Y; Hu, Q; Jogo, T; Kimura, Y; Mori, M; Nakanishi, R; Oki, E | 1 |
Mishima, S; Shitara, K | 1 |
Fong, WP; Hu, MT; Jin, Y; Li, YH; Luo, HY; Peng, JW; Qiu, MZ; Ren, C; Tan, Q; Wang, DS; Wang, FH; Wang, SB; Wang, ZQ; Zou, QF | 1 |
Kitagawa, C; Nishibori, R; Satoh, M; Shiraishi, K; Sugiyama, K; Yoshida, J | 1 |
Baba, E; Fujii, S; Fujitani, K; Oki, E; Shitara, K; Yamaguchi, K | 1 |
AbuTarif, M; Garimella, T; Iwata, H; Kastrissios, H; LaCreta, F; Lee, C; Lin, CC; Shahidi, J; Tamura, K; Wada, R; Watanabe, J; Yin, O; Zhang, L | 1 |
Chau, I; Fong, CY | 1 |
Hanayama, H; Hayase, S; Ito, M; Kanke, Y; Kono, K; Matsumoto, T; Mimura, K; Momma, T; Nakajima, S; Nakano, H; Neupane, P; Okayama, H; Saito, M; Saze, Z; Thar Min, AK; Watanabe, Y | 1 |
Amlashi, FG; Blum Murphy, M; Bozkurt, M | 1 |
Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K | 1 |
Kimura, M; Teramachi, H; Usami, E; Yoshimura, T | 1 |
Guo, H; Han, K; Tang, H; Yan, Y; Zhang, J; Zhang, L; Zhang, X; Zhuang, K | 1 |
Maenishi, O; Nakagawa, K; Nishio, K; Nonagase, Y; Ogitani, Y; Sakai, K; Takegawa, N; Tamura, T; Tsurutani, J; Yonesaka, K | 1 |
Akashi, K; Arimizu, K; Arita, S; Ariyama, H; Baba, E; Esaki, T; Hirano, G; Inadomi, K; Kajitani, T; Komoda, M; Kusaba, H; Kuwayama, M; Makiyama, A; Makiyama, C; Matsushita, Y; Oda, H; Ohmura, H; Shinohara, Y; Shirakawa, T; Uchino, K | 1 |
Grothe, W; Ho, J; Moehler, M; Syn, NL; Tai, BC; Unverzagt, S; Wagner, AD; Yong, WP | 1 |
Chen, D; Jin, R; Kang, Y; Li, W; Liang, G; Qiu, P; Wang, J; Wu, J; Xu, Q; Zhang, S; Zhou, P; Zhou, Y; Zhu, M | 1 |
Alessi, A; Battiston, C; Berenato, R; Caporale, M; Coppa, J; Cotsoglou, C; de Braud, F; Delconte, G; Di Bartolomeo, M; Fucà, G; Greco, G; Infante, G; Lazzati, S; Mazzaferro, V; Mennitto, A; Morano, F; Niger, M; Padovano, B; Pellegrinelli, A; Pietrantonio, F | 1 |
Gao, Z; Li, Z; Wang, P; Yan, J | 1 |
Bozkaya, Y; Demirci, NS; Erdem, GU; Ozdemir, NY; Yazici, O; Zengin, N | 1 |
Eisterer, W; Fridrik, MA; Greil, R; Gruenberger, B; Hejna, M; Huemer, F; Keil, F; Thaler, J; Trommet, V; Ulmer, H; Weiss, L; Wöll, E | 1 |
Das, K; Imamura, H; Nishikawa, K; Sugimoto, N; Taguri, M; Tan, P; Tsuburaya, A; Yoshida, K | 1 |
Hou, YC; Lei, CS; Lin, MT; Pai, MH; Yeh, SL | 1 |
Ando, T; Fujinami, H; Hosokawa, A; Kajiura, S; Matsubara, Y; Mihara, H; Nakata, N; Nanjo, S; Sugiyama, T; Takagi, H; Yoshita, H | 1 |
Chen, D; Chen, Z; Gao, J; Hu, Y; Huang, W; Ji, J; Li, B; Li, Z; Lin, X; Liu, Z; Shen, L; Wang, J; Zou, J | 1 |
Chen, G; Chen, J; Li, T; Liu, W; Liu, X; Qiao, Y; Shi, X; Shi, Y; Sun, Y; Wan, J; Wang, F; Wang, H; Xie, H; Xie, T; Zeng, Q; Zhou, L | 1 |
Assenat, E; Bouarioua, N; Cadiot, G; Coriat, R; Dahan, L; Dubreuil, O; Elhajbi, F; Ferru, A; Gangloff, A; Granger, V; Hautefeuille, V; Hentic, O; Kurtz, JE; Le Malicot, K; Lepage, C; Lepere, C; Lievre, A; Lombard-Bohas, C; Malka, D; Roquin, G; Scoazec, JY; Smith, D; Walter, T | 1 |
Endo, K; Imano, H; Kido, T; Kimura, Y; Morimoto, Y; Saito, R; Sasaki, T; Toda, H; Yoshino, K | 1 |
Chouda, Y; Inoue, H; Ishida, M; Kanazawa, T; Kubota, S; Miyake, S | 1 |
Al-Batran, SE; Galle, PR; Gehrke, N; Goepfert, K; Grimminger, P; Hegewisch-Becker, S; Maderer, A; Möhler, M; Nagel, M; Schattenberg, JM; Schulz, J; Thomaidis, T; Thuss-Patience, PC | 1 |
Chang, B; Jiang, X; Kariminia, S; Li, Q; Li, Y; Yan, H; Yang, L; Zhen, H | 1 |
Deguchi, T; Hanaki, T; Ichikawa, T; Kobayashi, D; Masubuchi, M; Shibata, A; Takase, T; Yaguchi, T | 1 |
Chi, Y; Jiang, ZC | 1 |
Aieta, M; Chiriacò, G; Conca, R; Multari, AG; Paganini, G; Petrioli, R; Rosellini, P; Roviello, G | 1 |
Doi, T; Fujisaki, Y; Iwasa, S; Iwata, H; Kadowaki, S; Modi, S; Park, H; Saito, K; Shahidi, J; Shitara, K; Sugihara, M; Takahashi, S; Tamura, K; Tsurutani, J; Yamaguchi, K | 1 |
Cardic, MB; Chao, Y; Chen, LT; Cunningham, D; de Gramont, A; Kang, YK; Kujundzic, M; Lim, HY; Park, SR; Ramos, FJ; Rees, C; Roy, AC; Tabernero, J; Yeh, CG | 1 |
Bueno, R; Choi, NC; Donahue, DM; Enzinger, PC; Fidias, PM; Fuchs, CS; Hong, TS; Jaklitsch, MT; Kwak, EL; Lanuti, M; Lee, MS; Mamon, HJ; Meyerhardt, JA; Rattner, DW; Ryan, DP | 1 |
Gao, B; Gao, Z; Gavine, PR; Ji, J; Ji, Q; Kilgour, E; Liu, K; Shen, D; Su, X; Tang, L; Xie, L; Xu, Y; Yin, X; Zhang, J; Zhang, L; Zhang, X; Zhou, M | 1 |
Abe, T; Fukaya, M; Itatsu, K; Nagino, M; Yokoyama, Y | 1 |
Ding, Y; Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Xie, L; Yang, Y; Yu, L; Yue, G; Zou, Z | 1 |
Boku, N; Fujiki, T; Fujino, K; Gemma, A; Kakihata, K; Masatani, S; Morita, S; Shiozawa, T; Tadokoro, J | 1 |
Guan, W; Liu, B; Qian, X; Shen, J; Wang, H; Wei, J; Yu, L; Yue, G; Zou, Z | 1 |
Goto, S; Kamigaki, T; Saito, M; Yano, K | 1 |
Gao, J; Li, Y; Peng, Z; Shen, L; Wang, X; Zhou, J | 1 |
Huang, XE; Huo, JG; Tang, JH; Wang, XN; Wei, GL | 1 |
Ahn, JS; Jeon, JR; Paik, SW; Park, CK; Park, TK; Sinn, DH; Yoo, HS | 1 |
Doki, Y; Furukawa, H; Kudo, T; Kurokawa, Y; Nishikawa, K; Oka, Y; Sakai, D; Satoh, T; Shimokawa, T; Tsujinaka, T | 1 |
Katayama, K; Nishino, T; Okitsu, H; Okitsu, N; Takahashi, Y; Tanaka, T | 1 |
Ohishi, K; Ori, T; Sunayama, K; Takeda, M | 1 |
Kadoya, N; Munemoto, M; Murata, S; Saito, H; Yoshimoto, K | 1 |
Fujitani, K | 1 |
Eguchi, T; Fujitake, S; Fujiwara, M; Ishigure, K; Ito, S; Kinoshita, T; Kodera, Y; Kojima, H; Mochizuki, Y; Ohashi, N | 1 |
Amagai, K; Boku, N; Denda, T; Fujita, Y; Hamamoto, Y; Kawai, H; Konishi, K; Mizusawa, J; Nakamura, K; Nishina, T; Nishisaki, H; Ohkawa, S; Ohtsu, A; Takashima, A; Tsuji, A; Tsuji, Y; Yamada, Y; Yamaguchi, K | 1 |
Baek, SK; Kim, HJ; Kim, HS; Kim, SY; Kim, TY; Lee, KW; Nam, BH; Ryu, MH; Zang, DY | 1 |
Case, RI; Chao, J; Cole, RO; Davis, ME; Eliasof, S; Han, H; Hwang, J; Lazarus, D; Lin, J; Peters, CG; Schluep, T; Wiley, DT; Yen, Y; Zuckerman, JE | 1 |
Hong, YS; Jung, KH; Kim, SY; Kong, SY; Lim, HS; Park, SR; Park, YI; Seong, MW | 1 |
Funahashi, H; Ishiguro, H; Kimura, M; Matsuo, Y; Miyai, H; Takeyama, H; Wakasugi, T | 1 |
Fan, WF; Liu, BR; Meng, LJ; Shen, J; Wang, J; Wang, L | 1 |
Fukuoka, T; Hasegawa, T; Hirakawa, K; Matsuzaki, T; Morisaki, T; Nishii, T; Yashiro, M | 1 |
Boku, N; Fukuda, H; Kato, K; Mizusawa, J; Nakamura, K; Ohtsu, A; Shimada, Y; Shirao, K; Takashima, A | 1 |
Boku, N; Esaki, T; Fujitani, K; Hamamoto, Y; Hironaka, S; Hyodo, I; Morita, S; Moriwaki, T; Nagase, M; Nishina, T; Okamoto, I; Shimodaira, H; Sugimoto, N; Tokunaga, S; Tsuda, M; Tsumura, T; Ueda, S; Ura, T; Yamaguchi, K; Yasui, H | 1 |
Elsing, C; Hannig, CV; Herrmann, C; Herrmann, T; Jäger, D; Stremmel, W | 1 |
Ando, T; Fujinami, H; Horikawa, N; Hosokawa, A; Kajiura, S; Kobayashi, T; Mihara, H; Minemura, M; Nishikawa, J; Note, M; Ogawa, K; Sugiyama, T; Terada, M; Ueda, A; Yabushita, K; Yoshita, H | 1 |
Inoue, K; Kobayashi, H; Murata, S; Naitoh, H; Tani, T; Yamamoto, H | 1 |
Cao, R; Chen, X; Geng, M; Li, P; Wang, L | 1 |
Amodio, A; Barba, M; Belli, F; Boggia, S; Di Lauro, L; Fattoruso, S; Giannarelli, D; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Vici, P | 1 |
Liu, B; Shen, J; Wang, J; Wang, L; Xie, L | 1 |
Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Passot, G; Roux, AS; Vaudoyer, D | 1 |
Abe, H; Ishibashi, H; Ishigaki, K; Itobayashi, E; Iwai, Y; Katagiri, T; Komata, S; Kubota, M; Matsushima, T; Miyakawa, A; Nakamura, A; Sakaguchi, Y; Shimura, H; Shimura, K; Suzuki, Y; Takashina, A; Tamura, T | 1 |
Aoyagi, H; Hasegawa, K; Isogai, J; Kaneko, J; Maejima, S; Matsui, T; Yoshida, T | 1 |
Arita, K; Haruki, S; Hiranuma, S; Ito, K; Matsumoto, A; Suzuki, K; Takiguchi, N; Usui, S | 1 |
Iwanaga, T; Iwasaki, Y; Karasawa, K; Kawasaki, K; Maeda, Y; Oohinata, R; Yajima, K; Yuu, K | 1 |
Hakamada, K; Kawasaki, H; Kimura, A; Muroya, T; Nagase, H; Nakai, M; Nakayama, Y; Okano, K; Wajima, N; Yonaiyama, S | 1 |
Fukunaga, M; Kaido, M; Kawabata, R; Kawase, T; Kimura, Y; Nakajima, Y; Ninomiya, H; Ohzato, H | 1 |
Aparicio, T; Breysacher, G; Chapet, S; Dousset, B; Faroux, R; Jouve, JL; Maillard, E; Martel-Lafay, I; Michel, P; Mornex, F; Nguyen, S; Pere-Verge, D; Pezet, D; Seitz, JF; Sobhani, I | 1 |
Caparello, C; Caponi, S; Falcone, A; Ginocchi, L; Lencioni, M; Lucchesi, M; Musettini, G; Vasile, E; Vivaldi, C | 1 |
Hamaguchi, T; Kubo, T; Matsumura, Y; Ochiya, T; Takigahira, M; Yanagihara, K | 1 |
Fujitani, K; Furukawa, H; Goto, M; Iijima, S; Imamura, H; Imano, M; Kurokawa, Y; Shimokawa, T; Sugimoto, N; Uedo, N | 1 |
Chen, Q; Li, A; Ni, P; Qiang, F; Røe, OD; Wang, M; Wang, S; Wu, X; Xu, S; Xu, W; Zhang, J; Zhang, R; Zhang, Y; Zhou, J | 1 |
Besanceney-Webler, C; Chen, EX; Cheng, J; Christos, P; Dilts, KT; Holloway, S; Keresztes, R; Lane, ME; Lin, J; Matulich, D; Ocean, AJ; Papetti, M; Schnoll-Sussman, F; Shah, MA; Sparano, JA; Ward, M; Wright, JJ; Xiang, J; Yantiss, RK | 1 |
Amagai, K; Azuma, M; Higuchi, K; Hosaka, H; Kanda, T; Koizumi, W; Moriwaki, T; Nakayama, N; Sakuyama, T; Sasaki, E; Sasaki, T; Sekikawa, T; Shimada, K; Takahashi, F; Takeda, Y; Takeuchi, M; Tanabe, S | 1 |
Wang, L; Wei, Y; Xie, H; Yao, W; Zeng, C; Zhou, H | 1 |
Hiotis, S; Jibara, G; Labow, DM; Romanoff, A; Sarpel, U; Shrager, B; Tabrizian, P; Yang, MJ | 1 |
Bai, L; Su, D | 1 |
Glimelius, B; Gubanski, M; Lind, PA | 1 |
Boku, N; Fukase, K; Goto, M; Koizumi, W; Mizusawa, J; Nishina, T; Ohtsu, A; Takahari, D; Takashima, A; Tamura, T; Tsuji, A; Yamada, Y; Yamaguchi, K; Yamazaki, K; Yoshino, T | 1 |
Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH | 1 |
Aitini, E; Amadori, D; Bajetta, E; Bidoli, P; Boni, C; Cantore, M; Carlomagno, C; Casaretti, R; Comella, G; Daniele, B; Di Bartolomeo, M; Di Costanzo, F; Di Fabio, F; Falcone, A; Floriani, I; Labianca, R; Landi, L; Marchet, A; Mini, E; Mosconi, S; Nitti, D; Pinotti, G; Pinto, C; Poli, D; Ravaioli, A; Rosati, G; Santoro, A | 1 |
Misawa, S; Miyamoto, M | 1 |
Cao, Y; Gong, J; Li, J; Li, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Wu, Y; Zhang, X; Zhou, J | 1 |
Chung, HY; Kang, BW; Kim, JG; Kwon, OK; Yu, W | 1 |
Abei, M; Endo, S; Hirai, S; Hirose, M; Hyodo, I; Saito, R; Suzuki, H; Ueno, T; Yamato, K | 1 |
Avital, I; Beane, JD; Beresnev, T; Langan, RC; Mullinax, JE; Pandalai, P; Rudloff, U; Schrump, D; Steinberg, SM; Stojadinovic, A; Toomey, MA; Walker, M; Webb, CC | 1 |
Aksoy, S; Benekli, M; Ekinci, AS; Günaydın, Y; Oksuzoglu, B; Özatlı, T; Ozdemir, N; Sendur, MA; Yazıcı, O; Yazılıtaş, D; Zengin, N | 1 |
Feng, JF; Huang, XE; Liu, J | 1 |
Fuse, N; Kim, JM; Kim, SY; Kim, TY; Kim, YH; Komatsu, Y; Lee, KH; Morita, S; Munakata, M; Nishio, K; Park, SH; Rha, SY; Saitoh, S; Sakata, Y; Sasaki, Y; Satoh, T; Ura, T; Yamada, Y; Yamaguchi, K; Yamamoto, E; Yasui, H; Zhang, Q | 1 |
Ito, S; Masui, H; Minami, Y; Mogaki, M; Morita, T; Takagawa, R; Watanabe, J | 1 |
André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M | 1 |
Fujii, T; Ikeda, T; Kimura, H; Nakayama, H; Sakai, Y | 1 |
Calkins, SM; Cinar, P; Kelley, RK; Venook, AP | 1 |
Aoyama, T; Hayashi, S; Hayashi, T; Kanazawa, A; Kunisaki, C; Masuda, M; Oshima, T; Rino, Y; Sato, T; Segami, K; Sugano, N; Yamamoto, N; Yoshikawa, T; Yukawa, H | 1 |
Asaoka, T; Endo, S; Fujitani, K; Fukuda, Y; Fukui, A; Fushimi, H; Harada, Y; Haraguchi, N; Hirao, M; Ikeda, M; Iwase, K; Kawada, J; Miyake, M; Miyamoto, A; Miyazaki, M; Nakamori, S; Nishikawa, K; Sekimoto, M; Takagi, M; Yamamoto, K | 1 |
Nakagawa, F; Nukatsuka, M; Saito, H; Sakata, M; Takechi, T; Uchida, J | 1 |
Akamaru, Y; Fujitani, K; Inagaki, H; Ishiguro, T; Miyashita, Y; Morita, S; Nakamura, M; Nishikawa, K; Sakamoto, J; Shigematsu, T; Sugimoto, N; Takagi, M; Tamura, S; Tokunaga, S; Tsuburaya, A; Tsujinaka, T; Yoshikawa, T | 1 |
Bang, YJ; Choi, IS; Han, SW; Im, SA; Kim, JH; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KH; Lee, KW; Oh, DY | 1 |
Arrojo, R; Cardillo, TM; Chang, CH; Goldenberg, DM; Govindan, SV; Liu, D; Rossi, EA; Sharkey, RM; Trisal, P | 1 |
Qiu, ZQ; Qiu, ZR | 1 |
Kakuta, S; Kou, T; Sugaya, M; Takayama, W; Yanagibashi, H; Yoneyama, Y | 1 |
Kang, WK; Kim, ST; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
Cardillo, TM; Chang, CH; Goldenberg, DM; Govindan, SV; McBride, WJ; Rossi, EA; Sharkey, RM; Wang, Y | 1 |
Chin, K; Fujii, M; Ichikawa, W; Kakeji, Y; Kawase, T; Kochi, M; Kunisaki, C; Matsuhashi, N; Nakajima, T; Nishikawa, K; Ohno, T; Takagane, A; Takeuchi, M; Tanabe, K; Terashima, M; Tsuji, A; Yoshida, K | 1 |
Choi, YJ; Kim, JH; Kim, SE; Kwon, HJ; Lee, HW; Moon, W; Park, MI; Park, SJ | 1 |
Skoropad, VY | 1 |
Amagai, K; Boku, N; Gotoh, M; Hamamoto, Y; Kawai, H; Mizusawa, J; Nakamura, K; Nakayama, N; Nishina, T; Ohtsu, A; Shimada, Y; Shirao, K; Yamaguchi, K; Yasui, H | 1 |
Chun, HJ; Park, SC | 1 |
Bang, YJ; Kim, TY; Oh, DY | 1 |
Choi, M; Kim, R; Mahipal, A | 1 |
Chen, S; Pan, M; Tong, Y; Zhang, L; Zhang, X | 1 |
Emi, Y; Ikeda, Y; Ishibashi, T; Nakao, S | 1 |
Amagai, K; Azuma, M; Bando, H; Chin, K; Fujii, H; Gotoh, M; Hamada, C; Hironaka, S; Hyodo, I; Imamura, H; Miwa, H; Nishikawa, K; Nishina, T; Niwa, Y; Shimada, K; Sugimoto, N; Tsuda, M; Tsuji, A; Yamada, Y; Yamaguchi, K; Yasui, H | 1 |
Auzolle, C; Bonnetain, F; Bouché, O; Brieau, B; Coriat, R; Ducreux, M; Goujon, G; Lecomte, T; Marthey, L; Pozet, A; Prieux, C; Rougier, P; Soibinet, P; Taieb, J; Tougeron, D; Zaanan, A | 1 |
Akiyama, Y; Hasuike, Y; Higuchi, I; Ishikawa, A; Miyamoto, M; Okada, A; Tanigawa, T | 1 |
Hayashida, H; Higaki, N; Miyake, Y; Nakane, S; Nezu, R; Oka, Y; Okada, K; Ueshima, S | 1 |
Hiratsuka, M; Ishibashi, Y; Ito, Y; Morita, A; Omori, K; Saito, H; Suda, H; Suematsu, Y; Takahashi, M; Wakabayashi, K | 1 |
Cho, SY; Han, JY; Kang, J; Kang, W; Kwon, JY; Lee, A; Lee, C; Min, S; Park, H | 1 |
Huang, J; Lyu, X; Tao, Y; Tian, Y; Wang, W; Wu, D; Yang, L | 1 |
Chao, J; Clark, AJ; Davis, ME; Lin, J; Webster, P; Wiley, DT; Yen, Y; Zuckerman, JE | 1 |
Fujiwara, Y; Kishi, K; Motoori, M; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M | 1 |
Esaki, T; Fujiya, T; Furukawa, H; Horita, Y; Imamoto, H; Imamura, H; Kimura, Y; Morita, S; Ninomiya, M; Nishikawa, K; Oono, R; Sasako, M; Sugimoto, N; Taguri, M; Takayama, O; Tan, P; Tsuburaya, A; Tsujinaka, T; Yabusaki, H; Yamada, Y | 1 |
Agatsuma, T; Hagihara, K; Naito, H; Ogitani, Y; Oitate, M | 1 |
Cho, YH; Kim, SN; Yoon, SY | 1 |
Cao, Z; Chen, Y; Gao, J; Jiang, Q; Li, Y; Liu, J; Luo, H; Xu, R; Yang, Z | 1 |
Cardillo, TM; Chang, CH; Goldenberg, DM; Liu, D; Wang, Y; Zalath, M | 1 |
Fukutomi, A; Hamauchi, S; Kawahira, M; Kawai, S; Kawakami, T; Kito, Y; Machida, N; Onozawa, Y; Todaka, A; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T; Yoshida, Y | 1 |
Anderegg, MC; Haj Mohammad, N; Mali, RMA; Ngai, LL; Ter Veer, E; van Laarhoven, HWM; van Oijen, MGH; van Valkenhoef, G | 1 |
Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H | 1 |
Krishnan, V; Liem, N; Peethala, PC; Subhash, VV; Tan, SH; Yan, FL; Yeo, MS; Yong, WP | 1 |
Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C | 1 |
Cheng, SY; Du, J; Li, J; Li, KC | 1 |
Gao, J; Gong, J; Li, J; Li, Y; Li, Z; Liu, Y; Lu, M; Lu, Z; Shen, L; Wang, X; Yang, L; Zhang, X; Zhou, J | 1 |
Boku, N; Hamaguchi, T; Honma, Y; Iwasa, S; Kato, K; Nagashima, K; Nishimura, T; Okita, N; Shimada, Y; Takashima, A; Yamada, Y | 1 |
Akamatsu, H; Furukawa, K; Ikehara, M; Kishi, K; Koh, M; Masuzawa, T; Suzuki, Y; Tanemura, M; Tei, M; Tsukada, R | 1 |
Fujiwara, T; Kagawa, S; Kikuchi, S; Kuroda, S; Nishizaki, M | 1 |
Iijima, S; Nishioka, K; Oshima, S; Takachi, K; Takemoto, H; Tsujimura, N; Uemura, Y | 1 |
Alsaied, O; Arora, N; Banerjee, S; Dauer, P; Dudeja, V; Giri, B; Majumder, K; Modi, S; Saluja, A; Von Hoff, D | 1 |
Cho, SH; Chung, IJ; Han, HS; Hong, YS; Kang, HJ; Kang, JH; Kim, JE; Kim, JH; Kim, JW; Kim, KP; Kim, SY; Kim, TW; Lee, JH; Lee, KT; Lee, KW; Lee, MA; Nam, BH; Oh, HS; Park, SR; Park, YI; Park, YS; Shin, DB; Song, EK; Zang, DY | 1 |
Amano, F; Kanai-Mori, A; Koike, A; Morishige, Y; Tamaki, R; Yanagihara, K | 1 |
Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J | 1 |
Barone, C; Pozzo, C | 1 |
Igarashi, T; Imai, H; Iwabuchi, T; Matsumoto, H; Obana, N; Ooyauchi, M; Sakamoto, K; Satou, Y | 1 |
Arai, H; Kashiwabara, M; Maruyama, H; Matsuda, A; Matsushita, A; Matsutani, T; Miyamoto, M; Mizutani, T; Nishi, Y; Sasajima, K; Suzuki, S; Tajiri, T; Yanagi, K; Yokoyama, T | 1 |
Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I | 1 |
Bang, YJ; Im, SA; Kim, DY; Kim, JH; Kim, TY; Lee, JS; Lee, KW; Lim, JH; Oh, DY; Seo, MD; Yi, HG | 1 |
Abe, T; Fukushima, T; Hamaguchi, Y; Masui, H; Mogaki, M; Nagahori, K; Nagahori, Y | 1 |
Adachi, K; Arimoto, Y; Nishio, K; Ohba, H; Ohtani, H; Shintani, M; Yui, S | 1 |
Ishii, Y; Mado, K; Manmoto, J; Masuda, H; Mazaki, T; Okame, H; Suzuki, K; Takayama, T | 1 |
Bekaii-Saab, T; Haghighat, P | 1 |
Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Nakashima, K; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H | 1 |
Hamaguchi, T; Kato, K; Matsumura, Y; Mihara, K; Nakajima, TE; Ochiya, T; Shimada, Y; Takigahira, M; Yamada, Y; Yanagihara, K; Yasunaga, M | 1 |
Fujimitsu, Y; Kojima, H; Kojima, T; Kure, N; Matsui, T; Mochizuki, Y; Uemura, T | 1 |
Fujii, Y; Ishiguro, H; Kimura, M; Kuwabara, Y; Mitsui, A; Ogawa, R | 1 |
al-shammaa Hassan, AH; Li, Y; Liu, SY; Lu, YL; Yang, GL; Yang, XJ; Yonemura, Y; Zhang, JW | 1 |
Ardito, R; Ariu, L; Boselli, S; de Braud, F; Di Meglio, G; Fazio, N; Lorizzo, K; Magni, E; Minchella, I; Nolè, F; Radice, D; Rocca, A; Squadroni, M; Zampino, MG | 1 |
Assersohn, L; Brown, G; Chong, G; Costello, C; Cunningham, D; Higgins, L; Leary, A; Norman, AR; Oates, J; Ross, PJ | 1 |
Furukawa, H; Imamura, H; Kishimoto, T; Miyazaki, Y; Ota, K; Tatsuta, M | 1 |
Blaszkowsky, LS; Clark, JW; Earle, CC; Enzinger, PC; Fidias, P; Fuchs, CS; Kulke, MH; Mayer, RJ; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Vincitore, MM; Zhu, AX | 1 |
Gennatas, C; Gennatas, S; Michalaki, V | 1 |
Fukumoto, T; Hachiya, O; Kamio, Y; Kimura, W; Nomura, T; Shibata, K; Takasu, N | 1 |
Hirano, N; Hoteya, S; Iizuka, T; Kikuchi, D; Yahagi, N | 1 |
Cao, W; Geng, M; Jiang, J; Jin, Y; Li, H; Lou, G; Ma, T; Xi, W; Yang, W | 1 |
Cannone, M; Casaretti, R; Comella, P; Franco, L; Greco, E; Leo, S; Lorusso, V; Maiorino, L; Mancarella, S; Massidda, B; Palmeri, S; Putzu, C; Roselli, M; Sandomenico, C; Vessia, G | 1 |
Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D | 1 |
Ilson, DH; Kelsen, DP; Ku, GY; Maki, RG; O'Reilly, EM; Saltz, LB; Schrag, D | 1 |
Fujimoto, H; Kawaguchi, K; Ohta, K; Seo, N; Urayama, M | 1 |
Mehta, RS; Raj, KP; Sanati, H; Zell, JA | 1 |
Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Ono, A; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T | 1 |
Chang, MH; Ji, SH; Jun, HJ; Kang, WK; Kim, HS; Kim, KH; Lee, J; Lim, DH; Lim, HY; Park, JO; Park, MJ; Park, SH; Park, YS; Uhm, JE; Yi, SY | 1 |
Harada, N; Hayashi, T; Sunaga, T; Suzuki, M; Suzuki, S; Tanaka, S | 1 |
Korbakis, D; Scorilas, A | 1 |
Han, H; Kim, HJ; Kim, SG; Kim, SH; Kwon, HC; Lee, S; Oh, SY; Seo, BG | 1 |
Fazzone, W; LaBonte, MJ; Ladner, RD; Lenz, HJ; Louie, SG; Manegold, PC; Wilson, PM | 1 |
Alonso-Orduña, V; Antón, A; Aranda, E; Cardenal, A; Carrato, A; Cervantes, A; Escudero, P; Galán, M; Gallego, J; Giralt, J; Laquente, B; Massutí, B; Rivera, F; Rodríguez, E; Sáenz, A; Tabernero, J; Vega-Villegas, ME; Yuste, AL | 2 |
Hishima, T; Iwanaga, T; Iwasaki, Y; Matsumoto, H; Nakano, D; Nunobe, S; Ohashi, M; Suzuki, Y; Takahashi, K; Yamaguchi, T | 1 |
Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J | 1 |
Daum, S; Ebert, MP; Flieger, D; Galle, PR; Geissler, M; Hoehler, T; Kanzler, S; Moehler, M; Raedle, J; Seufferlein, T | 1 |
Cho, SJ; Choi, IJ; Kim, CG; Kim, NK; Kim, YW; Kook, MC; Lee, JH; Lee, JS; Lee, JY; Park, SR; Park, YI; Ryu, KW | 1 |
Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N | 1 |
Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, J; Mroue, RM; Nasr, FL; Younes, FC | 1 |
Fujitani, K; Fukushima, N; Imamura, H; Ito, S; Kawashima, Y; Oshita, H; Sano, T; Sasako, M; Yamamoto, S; Yoshikawa, T | 1 |
Akashi, R; Kanda, K; Kiyozumi, T; Koba, I; Miyamoto, H; Sagara, K; Yamanouchi, T; Yoshida, M; Zinnouchi, K | 1 |
Igarashi, T; Kitagawa, Y; Kumagai, K; Nakamura, R; Saikawa, Y; Takahashi, T; Takeuchi, Y | 1 |
Chen, J; Chen, Z; Ge, J; Li, J; Li, X; Wu, S; Yin, J | 1 |
Kim, R; Lee, C; Wesolowski, R | 1 |
Ahn, JB; Chung, HC; Im, CK; Jeung, HC; Noh, SH; Rha, SY; Roh, JK; Shin, SJ | 1 |
Furuta, R; Hibi, S; Ina, K; Kataoka, T; Kawai, M; Kojima, S | 1 |
Jang, JS; Kim, BG; Kim, DK; Kim, HJ; Kim, MC; Kim, SG; Kim, SH; Kwon, HC; Lee, DM; Lee, S; Oh, SY | 1 |
Hang, M; Hang, X; Li, M; Mao, W; Sun, Q; Xu, W; Zhang, J | 1 |
Teng, KY; Xu, RH | 1 |
Boku, N; Doi, T; Fukuda, H; Koizumi, W; Nasu, J; Ohtsu, A; Saito, H; Sawaki, A; Shirao, K; Takiuchi, H; Yamaguchi, K; Yamamoto, S | 1 |
Ikeda, H; Kanagawa, T; Katoh, H; Kobayashi, K; Kodera, M; Oishi, M; Seshimo, K; Takita, K; Yamamura, M; Yamashita, Y; Yokomichi, N | 1 |
Asada, T; Chijiiwa, K; Eto, TA; Futami, S; Hidaka, H; Imada, S; Shibata, N; Shimayama, T; Takaya, T; Tanaka, S | 1 |
Nishida, T | 1 |
Kirishima, T; Marui, A; Matsuda, S; Mizumoto, M; Motoyoshi, T; Shintani, H; Takaaki, J; Takai, K; Yamashita, Y; Yoshikawa, T; Yoshinami, N | 1 |
Akasaka, O; Anan, H; Ando, T; Iwase, S; Kasama, M; Koh, R; Matsueda, R; Miwa, H; Morita, S | 1 |
Fukumoto, R; Hashimoto, M; Hirabayashi, S; Honda, I; Mase, T; Morioka, Y; Nagata, J; Nakanishi, K; Nishi, T; Onishi, E; Oya, H | 1 |
Hara, T; Hiramatsu, K; Hosoya, J; Kato, K; Kimura, A; Kojima, T; Machiki, Y; Otsuji, H; Sakuragawa, T; Tanaka, H; Tsuchiya, T; Yoshida, K | 1 |
Avital, I; Berger, A; Duffy, A; Giaccone, G; Goldspiel, BR; Kammula, US; Kemp, CD; Kerkar, SP; Kwong, KF; Quezado, M; Rosenberg, SA; Schrump, DS; Steinberg, SM; Toomey, MA; Venkatesan, A; Walker, M | 1 |
Hirakawa, M; Hirako, T; Koh, Y; Minami, S; Miyajima, N; Saitoh, T; Sasagawa, Y; Takanashi, K; Ueno, Y | 1 |
Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Yanagida, N | 1 |
Aoki, T; Igarashi, Y; Kobayashi, K; Komori, T; Matsumoto, T; Nishioka, K; Takachi, K; Tanizaki, K; Uemura, Y; Yamanaka, C | 1 |
Cho, SH; Go, SI; Kang, JH; Kim, HG; Kim, HJ; Kim, SH; Lee, GW | 1 |
Boku, N; Fukutomi, A; Hironaka, S; Kojima, T; Machida, N; Onozawa, Y; Sakamoto, T; Shimoyama, R; Taku, K; Todaka, A; Tomita, H; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yanagi, M | 1 |
Inokuchi, M; Kato, K; Kawano, T; Kojima, K; Sugihara, K; Yamada, H | 1 |
Fujii, M; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T | 2 |
Kitagawa, M; Koh, T; Kondo, Y; Nakagawa, N; Nanri, M; Oguro, A; Yamasaki, J | 1 |
Funai, S; Hatabe, S; Inoue, K; Kitano, Y; Tanaka, A | 1 |
Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK | 1 |
Fukunaga, M; Furukawa, H; Imamura, H; Kishimoto, T; Miyazaki, Y; Ohta, K; Ohzato, H; Shimizu, H; Tatsuta, M | 1 |
Fujita, H; Ichimura, K; Ikeda, H; Katoh, H; Kawai, Y; Kodera, M; Maejima, R; Oishi, M; Seshimo, K; Shibagaki, K; Takita, K; Tanaka, N; Toshima, T; Yamamura, M; Yamashita, Y; Yokomichi, N | 1 |
Akashi, I; Ashizawa, T; Hama, K; Hirano, T; Iwahori, T; Iwamoto, H; Jyojima, Y; Kihara, Y; Konnno, O; Nagao, T; Nakamura, Y; Segawa, M; Takeuchi, H; Yokoyama, T | 1 |
Brighenti, M; Buti, S; Dalla Chiesa, M; Donati, G; Lazzarelli, S; Passalacqua, R; Rovere, RK; Tomasello, G | 1 |
Ahn, BJ; Choi, MK; Heo, JS; Kang, WK; Kim, S; Lee, J; Lim, HY; Noh, JH; Park, JO; Park, SH; Park, YS; Sohn, TS; Yim, DS | 1 |
Boku, N; Fukutomi, A; Hamauchi, S; Hironaka, S; Machida, N; Onozawa, Y; Sakamoto, T; Taku, K; Taniguchi, H; Todaka, A; Tomita, H; Tsushima, T; Yamazaki, K; Yasui, H | 1 |
Allegrini, G; Andreuccetti, M; Cascinu, S; Cortesi, E; Falcone, A; Fontana, E; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Mentuccia, L; Merlano, M; Salvatore, L; Vasile, E | 1 |
Fleig, WE; Grothe, W; Grothey, A; Haerting, J; Kleber, G; Unverzagt, S; Wagner, AD | 1 |
Abbas, A; Bekaii-Saab, T; Burak, W; Lustberg, MB; Lustberg, ME; McCracken-Bussa, B; Otterson, G; Villalona-Calero, MA; Young, D | 1 |
Hirakawa, K; Matsuzaki, T; Nishii, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
Farhat, FS; Ghosn, MG; Kattan, J | 1 |
Fukushima, M; Hata, M; Ichikawa, C; Kirii, Y; Miyairi, J; Miyamoto, M; Ota, H; Takagi, H | 1 |
Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E | 1 |
Asaka, M; Fuse, N; Kato, T; Komatsu, Y; Kudo, M; Kunieda, Y; Meguro, T; Miyagishima, T; Sakata, Y; Tateyama, M; Wakahama, O; Yuki, S | 1 |
Hata, T; Ishizu, H; Kawamura, H; Kondo, Y; Masuko, H; Okada, K; Tanaka, K; Tanioka, T; Tsunoda, Y; Watarai, H; Yamagami, H; Yokota, K; Yokota, R | 1 |
Egashira, Y; Gotoh, M; Higuchi, K; Kawabe, S; Kii, T; Kojima, Y; Kuwakado, S; Takiuchi, H; Tanigawa, N; Yoshida, M | 1 |
Fukuda, S; Hanada, N; Hirose, K; Ishiguro, A; Itoh, J; Kawasaki, H; Kijima, H; Matsumoto, Y; Saijo, Y; Suzuki, K; Takahata, T; Tanaka, S | 1 |
Berglund, A; Fernebro, E; Flygare, P; Glimelius, B; Gubanski, M; Johnsson, A; Kadar, L; Karlberg, I; Lind, PA | 1 |
Hamaguchi, T; Hirashima, Y; Kato, K; Nishitani, H; Okita, N; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Takeshita, S; Yamada, Y | 1 |
Ahn, BJ; Choi, MK; Kang, WK; Ko, JW; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
Breithaupt, K; Thuss-Patience, PC | 1 |
Hosono, S; Ito, H; Ito, S; Kawai, H; Kawase, T; Matsuo, K; Muro, K; Sawaki, A; Shibata, T; Shitara, K; Tajima, K; Takahari, D; Tanaka, H; Ura, T; Watanabe, M; Yatabe, Y; Yokota, T | 1 |
Cho, SJ; Choi, IJ; Kim, CG; Kim, NK; Kim, YW; Kong, SY; Lee, JH; Lee, JY; Park, SR; Park, YI; Rhee, J; Ryu, KW | 1 |
Han, B; Kang, WK; Kim, JA; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS | 1 |
Furukawa, K; Kanazawa, Y; Mamada, Y; Uchida, E; Yamada, T; Yokoi, K | 1 |
Dong, CM; Kang, MF; Liu, Y; Luo, MQ | 1 |
Galle, PR; Geißler, M; Kanzler, S; Kubicka, S; Lordick, F; Moehler, M; Mueller, A; Schwarz, S; Seufferlein, T; Trarbach, T | 1 |
Chen, JF; Gu, DY; Huang, HY; Wang, DL; Xu, Z | 1 |
Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kojima, O; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Oshima, S; Sakamoto, T; Yamaguchi, M | 1 |
Endo, W; Fujie, Y; Fukunaga, H; Hojou, S; Maeura, Y; Ota, H; Shimizu, K; Toyoda, Y; Yoshioka, A; Yoshioka, S | 1 |
Aoyagi, H; Hamada, S; Hasegawa, K; Higuchi, T; Isogai, J; Kaneko, J; Katsuta, E; Maejima, S; Ono, H; Saguchi, M; Someno, Y; Sugihara, K; Takahata, T; Yoshida, M | 1 |
Doi, T; Hoshi, M; Iijima, S; Kato, A; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Oshima, S; Sakamoto, T | 1 |
Asami, S; Idani, F; Kin, H; Komoto, S; Kubo, S; Kubota, T; Kumano, K; Kurose, Y; Muro, M; Nojima, H; Sasaki, H; Takakura, N; Yoshioka, T | 1 |
Akabane, H; Inagaki, M; Nakano, S; Shomura, H; Yanagida, N | 1 |
Iwanaga, T; Iwasaki, Y; Maeda, Y; Matsumoto, H; Nakano, D; Ohashi, M; Ohhinata, R; Sasaki, E; Takahashi, K; Yamaguchi, T | 1 |
Chika, N; Dan, N; Goto, H; Hosokawa, T; Kakimoto, M; Kato, H; Koshiishi, H; Masuda, T; Matsuyama, T; Mitsuhashi, Y; Nishida, K; Okamura, T; Sakamoto, K; Tokita, H; Yoshimura, T | 1 |
Ashley, S; Charalambous, H; Chau, I; Cunningham, D; Hawkes, E; Koukouma, A; Okines, AF; Papamichael, D; Rao, S | 1 |
Cai, X; Guo, WJ; Li, J; Liu, X; Tian, S; Zhang, XW | 1 |
Lin, J; Liu, SX; Meng, XX; Shao, XQ; Wu, XM; Xiao, HS; Zhang, XN; Zhu, L | 1 |
Hamaguchi, T; Hirashima, Y; Kato, K; Matsubara, J; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Taniguchi, H; Yamada, Y | 1 |
Aoyama, T; Cho, H; Hayashi, T; Ogata, T; Tsuburaya, A; Watanabe, T; Yoshikawa, T | 1 |
Chon, HJ; Chung, HC; Jeung, HC; Kim, HS; Noh, SH; Park, HS; Rha, SY; Roh, JK; Shin, SJ | 1 |
Ito, S; Kawai, H; Kondo, C; Matsuo, K; Mizota, A; Muro, K; Nomura, M; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T; Yokota, T | 1 |
Chin, K; Esaki, T; Furukawa, H; Hamada, C; Iishi, H; Imamoto, H; Imamura, H; Narahara, H; Sakata, Y; Tsuburaya, A | 1 |
Ito, S; Kawai, H; Muro, K; Sawaki, A; Shitara, K; Tajika, M; Takahari, D; Ura, T; Yokota, T | 1 |
Takiuchi, H | 1 |
Chayama, K; Kitadai, Y; Kodama, M; Ohara, E; Ohnishi, M; Shinagawa, K; Sumida, T; Tanaka, M; Tanaka, S; Yasui, W | 1 |
Hosojima, Y; Miura, T; Nakamura, J; Nakazawa, Y; Ozeki, Y; Takahashi, T; Yamada, S; Yamazaki, H; Yanagi, M | 1 |
Bjerregaard, JK; De Stricker, K; Gjerstorff, MF; Hansen, TP; Jensen, HA; Pfeiffer, P; Schoennemann, KR; Vestermark, LW | 1 |
Bakrin, N; Cotte, E; Gilly, FN; Glehen, O; Mohamed, F; Passot, G; Steghens, A; Tod, M | 1 |
Hirakawa, K; Miwa, A; Qiu, H; Yashiro, M; Zhang, X | 1 |
Imaoka, S; Kanoh, T; Kimura, Y; Min Kim, H; Monden, T; Nakano, Y; Ohnishi, T; Tono, T; Yano, H | 1 |
Arai, Y; Boku, N; Denda, T; Fujii, H; Hamaguchi, T; Hyodo, I; Iwase, H; Koizumi, W; Ohtsu, A; Saito, H; Shirao, K; Takiuchi, H; Yoshida, M | 1 |
Kimura, Y; Kitajima, M; Komatsu, Y; Oda, H; Saji, S; Sakamoto, J; Sakata, Y; Sakurai, J; Tajima, Y; Takahashi, M; Takahashi, Y; Tamura, S; Tatebe, S; Wakasugi, T | 1 |
Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K | 1 |
Hirano, T; Matsumoto, K; Morisaki, T; Sada, M | 1 |
Chen, DY; Qi, Q; Zhao, WY | 1 |
Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M | 1 |
Chiba, F; Kiyozaki, H; Konishi, F; Saito, M; Shuto, C; Takata, O; Yamada, S; Yoshida, T | 1 |
Fujii, S; Fukahori, M; Godai, TI; Imada, T; Kunisaki, C; Makino, H; Masuda, M; Numata, M; Oshima, T; Rino, Y; Sato, T | 1 |
Bichev, D; Breithaupt, K; Deist, T; Dogan, Y; Gebauer, B; Hinke, A; Kretzschmar, A; Reichardt, P; Schumacher, G; Thuss-Patience, PC | 1 |
Fujii, Y; Hamano, K; Hanashima, M; Kuga, T; Oka, K; Yamashita, A | 1 |
Chen, QQ; Gao, XP; Li, W; Pan, SY; Sun, J | 1 |
Auby, D; Becouarn, Y; Bellera, C; Brunet, R; Cany, L; Dauba, J; Fonck, M; Legoux, JL; Mathoulin-Pélissier, S; Mertens, C; Rainfray, M; Smith, D; Soubeyran, P; Terrebonne, E; Traissac, L | 1 |
Kageyama, S; Katayama, N; Mizuno, T; Nomura, H; Oda, H; Saito, K; Tamaru, S; Yamashita, Y | 1 |
Aoki, Y; Arimura, Y; Goto, A; Igarashi, H; Itoh, M; Kaneto, H; Kobayashi, T; Matsunaga, Y; Okuda, H; Onodera, K; Shimizu, H; Shinomura, Y; Sukawa, Y; Suzuki, K; Wakasugi, H; Yawata, A; Yonezawa, K | 1 |
Aoyama, M; Asai, K; Ebi, M; Hirata, Y; Joh, T; Kamiya, T; Kataoka, H; Kubota, E; Mizoshita, T; Mori, Y; Murakami, K; Okamoto, Y; Shimura, T; Tanaka, M; Tanida, S | 1 |
Dumke, K; Krüger, M; Reymond, M; Weissinger, F | 1 |
Hasegawa, T; Hirakawa, K; Matsuzaki, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
Buhr, HJ; Fusi, A; Hotz, B; Hotz, HG; Keilholz, U | 1 |
Chen, L; Davis, M; Gaur, S; Wang, Y; Yen, T; Yen, Y; Zhou, B | 1 |
He, YJ; Li, YH; Luo, HY; Qiu, MZ; Ruan, DY; Teng, KY; Wang, FH; Wang, ZQ; Xu, RH | 1 |
Goh, PG; Jeong, HY; Kim, ES; Kim, SH; Kim, YJ; Lee, BS; Lee, ES; Lee, SY; Moon, HS; Sung, JK | 1 |
Bechter, O; Dlaska, M; Eisterer, W; Fridrik, MA; Greil, R; Grünberger, B; Mayrbäurl, B; Obrist, P; Russ, G; Thaler, J; Wöll, E; Zabernigg, A | 1 |
Danno, K; Imaoka, S; Kagara, N; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakano, Y; Ohnishi, T; Taniguchi, H; Tohno, T | 1 |
Iwanaga, T; Iwasaki, Y; Maeda, Y; Ohashi, M; Ohinata, R; Omuro, Y; Onoyama, H; Sasaki, E; Shimoyama, T; Tateishi, Y | 1 |
Furuta, T; Iwaizumi, M; Miyajima, H; Nishino, M; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Uotani, T; Yamada, T; Yamade, M | 1 |
Bourgeois, V; Ferte, C; Hebbar, M; Ladrat, L; Lindet, C; Mariette, C; Peugniez, C; Romano, O; Triboulet, JP | 1 |
Bjerregaard, JK; Nielsen, KM; Pfeiffer, P; Schønnemann, KR; Yilmaz, M | 1 |
Baek, SK; Cho, KS; Jeong, JH; Kim, SY; Yoon, HJ | 1 |
Hwang, IG; Kang, JH; Kang, WK; Kwon, HC; Lee, J; Lee, SC; Lee, SI; Lim, DH; Lim, HY; Nam, E; Oh, SY; Park, JO; Park, KW; Park, SH; Park, YS; Shin, DB | 1 |
Ikeda, T; Minamoto, K; Yuasa, I | 1 |
Abe, K; Akazawa, Y; Fukuda, Y; Isomoto, H; Mizuta, Y; Nakao, K; Ogihara, K; Shoji, H; Takeshima, F; Tsutsumi, T | 1 |
Chang, HM; Jo, JC; Kang, YK; Kim, HS; Kim, M; Kim, TW; Lee, HJ; Lee, JL; Ryu, MH; Shin, JG | 1 |
Lordick, F | 1 |
Fukuda, Y; Imamura, Y; Kouyama, M; Kuratsune, M; Nakamitsu, A; Ohta, H; Yokoyama, S | 1 |
Boku, N; Doyama, H; Fukutomi, A; Machida, N; Onozawa, Y; Taniguchi, H; Todaka, A; Tsuji, K; Tsushima, T; Yamazaki, K; Yasui, H; Yokota, T | 1 |
Edagawa, A; Eguchi, D; Ikeda, Y; Itoh, S; Kawanaka, H; Kawasaki, K; Korenaga, D; Koushi, K; Okuyama, T; Shinohara, S; Takenaka, K | 1 |
Adenis, A; Adler, G; Aparicio, J; Barcelo, JR; Canon, JL; Cassinello, J; Castanon, C; Cunningham, D; D'Hondt, L; Fonseca, E; Garcia Giron, C; Hawkins, R; Hossfeld, DK; Kerger, J; Lofts, F; Lopez-Vivanco, G; Misset, JL; Mousseau, M; Nicolson, M; Rixe, O; Rodriguez, R; Roy, A; Schalhorn, A; Schoffski, P; Sörbye, H | 1 |
Asukai, K; Hasegawa, I; Horiguchi, N; Koguchi, H; Matsunaga, S; Miura, A; Ohno, T; Sakakibara, K; Shimizu, S; Togawa, S | 1 |
He, AN; Lin, F; Min, DL; Qi, WX; Shen, Z; Sun, YJ; Tang, LN; Yao, Y | 1 |
Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO | 1 |
Gotoda, H; Imai, A; Ishigaki, S; Kobayashi, T; Nishikawa, M; Osada, T; Suzuki, T | 1 |
Alkis, N; Arpacı, E; Benekli, M; Berk, V; Bilici, A; Budakoglu, B; Buyukberber, S; Coskun, U; Dane, F; Demirci, U; Gumus, M; Inal, A; Isıkdogan, A; Kaya, AO; Ozkan, M; Yumuk, F | 1 |
Berger, A; Brieau, B; Dubreuil, O; Landi, B; Lepère, C; Markoutsaki, T; Rougier, P; Roussel, H; Taieb, J; Trouilloud, I; Vaillant, JN; Zaanan, A | 1 |
Cuenod, CA; Dubreuil, O; Fabre, M; Kourie, HR; Landi, B; Markoutsaki, N; Palazzo, L; Rahmi, G; Rougier, P; Roussel, H; Taieb, J; Van der Stiegel, M | 1 |
Cho, EK; Chung, M; Hong, J; Kim, HS; Lee, JH; Lee, WK; Park, J; Park, SH; Park, YH; Shin, DB; Sym, SJ | 1 |
Ilson, DH; Ku, GY | 1 |
Campbell, JC; Capanu, M; Ilson, DH; Janjigian, YY; Kelsen, DP; Ku, GY; Shah, MA | 1 |
Cinar, V; Erdik, B; Oyan, B; Ozturk, MA; Ozveren, O | 1 |
Bang, YJ; Choi, IS; Han, SW; Im, SA; Kang, EJ; Kim, JH; Kim, JS; Kim, JW; Kim, TY; Kim, YJ; Lee, JS; Lee, KW; Oh, DY | 1 |
Aoyagi, H; Hasegawa, K; Isogai, J; Iwata, N; Kaneko, J; Katsuta, E; Maejima, S; Yoshida, T | 1 |
Kataoka, M; Miyazawa, K; Oeda, Y; Tonooka, T; Wakatsuki, K; Yoshioka, S | 1 |
Doi, T; Hoshi, M; Iijima, S; Ikeda, K; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Miyo, M; Nagase, H; Oshima, S; Sakamoto, T | 1 |
Funaki, H; Kaida, D; Kinami, S; Kosaka, T; Morioka, E; Nakano, Y; Noguchi, M; Ohnishi, T; Ohno, Y; Omote, K; Tomita, Y; Ueda, N | 1 |
Etoh, T; Hayashi, H; Inoue, K; Itoh, K; Kawamura, Y; Kikuyama, M; Kimura, M; Matsumura, T; Minami, S; Sonobe, M; Suzuki, T; Takagi, M; Tsuji, D; Utsuki, H; Yamazaki, T | 1 |
Fragoulis, EG; Korbakis, D; Scorilas, A | 1 |
Ajani, JA; Baker, J; Charnsangavej, C; Feig, BW; Ho, L; Mansfield, PF; Pisters, PW | 2 |
Cho, YK; Choi, J; Joo, CH; Kim, J; Kim, JH; Kim, YK; Lee, B; Lee, H | 1 |
Hirose, T; Kobayashi, A; Yamada, T | 1 |
Höffken, K; Kliche, KO; Kubsch, K; Masri-Zada, R; Raida, M | 1 |
Gallagher, CJ; Shamash, J; Slater, S; Slevin, ML; Wilson, P | 1 |
Hayashi, K; Kuniyasu, H; Kuraoka, K; Nakayama, H; Oue, N; Shigeishi, H; Yasui, W | 1 |
Asami, T; Imada, T; Kokawa, A; Morimoto, M; Saito, T; Shirato, K; Sugimori, K; Tanaka, K; Tomita, N | 1 |
Huang, HX; Li, GS; Yang, CX | 1 |
Adachi, A; Hashimoto, D; Ishida, H; Itoyama, S; Murata, N; Sobajima, J | 1 |
Ebuchi, M; Hasegawa, K; Maruyama, M; Nagahama, T; Natsui, S; Ochiai, T; Takashima, I | 1 |
Hata, Y; Itoh, T; Maeda, Y; Matsuoka, S; Nakajima, N; Osada, T; Sano, F | 1 |
Baek, M; Bang, YJ; Cho, HN; Ha, JH; Jeoung, DI; Kim, HY; Lee, DY; Lee, HS; Lee, S; Lee, YS | 1 |
Gotoh, M; Katsu, K; Kawabe, S; Ohta, S; Takiuchi, H | 1 |
Baba, Y; Hayashi, N; Iyama, K; Marutsuka, T; Ogawa, M; Shimada, S; Yokoyama, S | 1 |
Fujitani, K; Hirao, M; Tsujinaka, T | 1 |
Aoki, F; Kaminishi, M; Mafune, K; Shimizu, N; Shimoyama, S; Tatsutomi, Y | 1 |
Alberts, SR; Cha, SS; Goldberg, RM; Jatoi, A; Kardinal, CG; Mailliard, JA; Morton, RF; Nair, S; Rowland, KM; Sargen, D; Stella, PJ; Tirona, MT | 1 |
Bugat, R | 1 |
Van Cutsem, E; Wilke, HJ | 1 |
Sawabu, N | 1 |
Jin, ML; Li, J; Li, Y; Shen, L; Yang, BQ; Zhang, XD | 1 |
Amano, K; Hanyu, F; Hayashi, T; Imazato, M; Suzuki, M; Suzuki, S; Takeo, Y; Tanaka, S | 1 |
Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K | 1 |
Kinoshita, H; Kitaura, T; Nakae, S; Onoyama, H; Sainoh, K; Saitoh, Y; Shiroiwa, H; Sugihara, S; Takahashi, T; Takao, S; Toyota, J; Urakawa, T; Yamamoto, M | 1 |
Fukuda, K; Kimura, F; Kokufu, I; Tanei, T; Taniguchi, H; Yamada, K; Yamamoto, M; Yano, T | 1 |
Koo, WH; Lim, ST; Lim, WT; Wong, NS | 1 |
Bugat, R; Catane, R; Clemens, M; Di Betta, D; Ducreux, M; Fages, B; Figer, I; Gips, M; Jacques, C; Klein, B; Knuth, A; Köhne, CH; Niederle, N; Preusser, P; Shani, A; Thuss-Patience, P; Wilke, HJ | 1 |
Galle, PR; Haas, U; Heike, M; Hertkorn, C; Hoehler, T; Moehler, M; Schimanski, C; Siebler, J | 1 |
Azuma, M; Higuchi, K; Kitamura, T; Koizumi, W; Nagaba, S; Nakayama, N; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
Gamoh, M; Kanamaru, R; Mitachi, Y; Saitoh, S; Sakata, Y; Sekikawa, K; Terashima, M; Yoshioka, T | 1 |
Benson, AB; Blanke, CD; Hecht, JR; Lenz, HJ | 1 |
Inoue, H; Mori, M; Ohta, M; Sadanaga, N; Tanaka, F; Yamaguchi, H | 1 |
Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T | 1 |
Baba, H; Kakeji, Y; Maehara, Y; Oki, E; Tokunaga, E; Ushiro, S; Watanabe, M | 1 |
Goto, M; Hiraide, Y; Matsumoto, T; Saito, E; Takada, T | 1 |
Akiyama, T; Doi, T; Hirata, K; Homma, H; Iyama, S; Kida, M; Kogawa, K; Mezawa, S; Murakami, K; Murase, K | 1 |
Arai, T; Goto, A; Hamaguchi, T; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y; Yasui, H | 1 |
Cohen, D; Hiotis, S; Lin, K; Marcus, SG; Newman, E; Potmesil, M; Rothberger, A; Thompson, S; Wong, K | 1 |
Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS | 1 |
Akagi, Y; Hashimoto, Y; Ito, K; Murakami, Y | 1 |
Sasako, M; Ushijima, T | 1 |
Kitakata, H; Mai, M; Minamoto, T; Omote, K; Takahashi, Y; Yamashita, K; Yasumoto, K | 1 |
Hirao, K; Hirasaki, S; Hyodo, I; Kajiwara, T; Tsuzuki, T | 1 |
Bae, JM; Choi, IJ; Choi, JY; Chun, JH; Kim, HK; Kim, YW; Lee, HG; Lee, JS; Ryu, KW; Yoon, SM | 1 |
Avadhani, A; Karrison, T; Kindler, HL; Mani, S; Vokes, EE; Wade-Oliver, K | 1 |
Hori, S; Imada, T; Ishiki, K; Ishioka, H; Mizuno, M; Motoi, M; Nagahara, Y; Okamoto, T; Take, S; Yoshida, T | 1 |
Hiki, N; Imamura, K; Kaminishi, M; Katayama, A; Mafune, K; Motoi, T; Oohashi, K; Shimizu, N; Shimoyama, S; Yamaguchi, H | 1 |
Chin, K; Ishihara, S; Maruyama, M; Nakajima, T; Ohta, K; Ohyama, S; Takahashi, T; Yamao, T | 1 |
Bae, JM; Chang, HJ; Choi, IJ; Chun, JH; Kang, HC; Kim, E; Kim, HK; Kim, IH; Kim, IJ; Kim, JH; Lim, HS; Park, JG; Park, JH | 1 |
Kawabata, Y; Kusumoto, C; Miyamoto, K | 1 |
Sulkes, A | 1 |
Brank, A; Camp, ER; Hochwald, SN; Li, J; MacKay, SL; Minnich, DJ; Moldawer, LL | 1 |
Androulakis, N; Boukovinas, I; Christophilakis, Ch; Georgoulias, V; Kotsakis, A; Kouroussis, Ch; Polyzos, A; Potamianou, A; Souglakos, J; Syrigos, K; Vardakis, N | 1 |
Ajani, JA; Andrassy, RJ; Blakely, ML; Harting, MT; Herzog, CE; Lally, KP | 1 |
Kitajima, M; Komatsu, Y; Kubota, T; Mai, M; Saji, S; Sakamoto, J; Takahashi, Y; Takeuchi, T; Tanigawara, Y; Toge, T | 1 |
Cecchin, E; Toffoli, G | 1 |
Arsène, D; Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Etienne, PL; Giovannini, M; Guérin-Meyer, V; Kaminsky, MC; Lledo, G; Milan, C; Mitry, E; Paitel, JF; Raoul, JL; Rougier, P; Seitz, JF | 1 |
Hejna, M; Raderer, M; Wöhrer, SS | 1 |
Ando, M; Maruyama, M; Nagahama, T | 1 |
Kitajima, M; Kubota, T; Mai, M; Saji, S; Sakamoto, J; Takahashi, Y; Takeuchi, T; Toge, T | 1 |
Iishi, H; Narahara, H; Sugimoto, N; Tatsuta, M | 1 |
Akiyama, Y; Aoki, K; Fujiwara, H; Iwaya, T; Kimura, Y; Nakaya, T; Saito, K | 1 |
Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T | 2 |
Li, YS | 1 |
Cai, X; Guo, YW; Lin, F; Sun, YJ; Tang, XC; Yao, Y; Zhao, H | 1 |
Ilson, D; Kelsen, DP; Shah, MA | 1 |
Ji, J; Ji, YB; Lin, YZ; Liu, BY; Yuan, F; Zhang, J; Zhu, ZG | 1 |
Im, YH; Jung, CW; Kang, JH; Kang, WK; Kim, K; Kim, ST; Kim, WS; Lee, J; Lee, SH; Park, JO; Park, K; Park, KW; Park, YS | 1 |
Silberman, H | 1 |
Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB | 1 |
Eimermacher, A; Flieger, D; Galle, PR; Geer, T; Gracien, E; Heike, M; Höhler, T; Junginger, T; Menges, M; Moehler, M; Siebler, J; Wein, A | 1 |
Altinbas, M; Coskun, HS; Er, O; Gursoy, S; Kucuk, C; Ozkan, M; Solak, Y | 1 |
Caponigro, F; Facchini, G; Iaffaioli, RV; Nasti, G | 1 |
Fujii, M; Kasakura, Y; Kochi, M; Morishita, Y; Sato, K; Takayama, T; Yamagata, M | 1 |
Fujita, S; Hirota, M; Inoue, Y; Masaki, K; Nomura, M; Sakao, J; Souda, S | 1 |
Philip, PA | 1 |
Hihara, J; Ohta, K; Tanabe, K; Toge, T; Yamaguchi, Y; Yoshida, K | 1 |
Belkhiri, A; El-Rifai, W; Knuutila, S; Moskaluk, C; Pidkovka, N; Zaika, A | 1 |
Ariyama, H; Baba, E; Harada, M; Kusaba, H; Mitsugi, K; Nakano, S; Qin, B; Shibata, Y; Takii, Y; Tanaka, R | 1 |
Araki, H; Ishizaki, M; Kamiyama, Y; Kawaguchi, Y; Komiyama, Y; Nakagawa, A; Nishimura, N; Takahashi, H | 1 |
Akiba, Y; Hibi, T; Higuchi, H; Iizuka, H; Izumiya, M; Nagata, H; Takaishi, H; Yamagishi, Y | 1 |
Ajani, JA; Baez, L; Becerra, CR; Cohn, A; De Jager, R; Feit, K; Kamida, M; Major, P; Silva, A; Takimoto, C | 1 |
Fujitani, K; Furukawa, H; Gotoh, M; Iishi, H; Katsu, K; Kawabe, S; Narahara, H; Taguchi, T; Takiuchi, H; Tatsuta, M; Tsujinaka, T | 1 |
Ishiguro, A; Mizuno, Y; Munakata, M; Sakata, Y; Shitara, K; Wada, R | 1 |
Kato, T; Masuoka, HO; Sato, K; Tamahashi, N; Yano, H | 1 |
Laurent-Puig, P; Lièvre, A | 1 |
Ando, M; Boku, N; Hasebe, T; Hyodo, I; Miyata, Y; Nagashima, F; Ochiai, A; Ohtsu, A; Saito, H; Sakata, Y; Yoshida, S | 1 |
Furukawa, H; Imamura, H; Kishimoto, T; Tatsuta, M; Yamamoto, K | 1 |
Battaglia, C; Colucci, G; Di Bisceglie, M; Gebbia, N; Gebbia, V; Giuliani, F; Maiello, E; Molica, S; Vinciarelli, G | 1 |
Kanbe, M; Osada, M | 1 |
Bae, SH; Baek, JH; Chung, HY; Do, YR; Hyun, MS; Kim, DH; Kim, JG; Kim, MK; Kwon, KY; Lee, KB; Lee, KH; Park, KU; Ryoo, HM; Sohn, SK; Song, HS; Yu, W | 1 |
Hiotis, S; Hochster, H; Marcus, S; Muggia, F; Newman, E; Norwood, B; Potmesil, M; Ryan, T; Wendell, M; Yee, H | 1 |
Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kim, H; Kulke, MH; Mayer, RJ; Michelini, AL; Ryan, DP; Vincitore, MM | 1 |
Fujita, J; Hoshimoto, S; Kato, R; Kato, T; Morise, Z; Sugioka, A | 1 |
Aiko, S; Ishizuka, T; Kumano, I; Maehara, T; Sakano, T; Sugiura, Y; Yoshizumi, Y | 1 |
Arveux, P; Bedenne, L; Bonnetain, F; Bouché, O; Conroy, T; Etienne, PL; Giovannini, M; Girault, C; Mitry, E; Raoul, JL; Rougier, P; Seitz, JF | 1 |
Ichikawa, W; Inokuchi, M; Kawano, T; Kojima, K; Nihei, Z; Sugihara, K; Yamada, H; Yamashita, T | 1 |
Goto, M; Katsu, K; Kawabe, S; Kii, T; Kuwakado, S; Nishitani, H; Ohta, S; Takiuchi, H; Tanaka, T | 1 |
Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C | 1 |
Bae, JM; Choi, IJ; Chun, JH; Kim, CG; Kim, HK; Kim, YW; Lee, JH; Lee, JS; Park, SR; Ryu, KW; Yu, MS | 1 |
Baek, JH; Chae, YS; Cho, GJ; Choi, YJ; Chung, JS; Jeon, SB; Jung, HY; Kim, DH; Kim, JG; Lee, KB; Shin, HJ; Sohn, SK; Yu, W | 1 |
Kandabashi, K; Maeda, Y; Mikoshiba, M; Okamoto, R; Omuro, Y; Sasaki, E; Sasaki, T | 1 |
Hoshihara, Y; Hoteya, O; Iizuka, T; Udagawa, H; Yahagi, N; Yamamoto, T | 1 |
Chung, HC; Jeung, HC; Noh, SH; Rha, SY; Roh, JK | 1 |
Lenz, HJ; Park, DJ | 1 |
Chen, YX; Jiang, GM; Tian, F; Zhao, JW | 1 |
Anai, H; Anegawa, G; Honda, M; Kai, T; Kaneko, S; Masuda, T; Nakamura, Y; Ohta, R; Saeki, H; Yokoyama, S | 1 |
Hirakawa, K; Ren, J; Yashiro, M; Zhang, X | 1 |
Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U | 1 |
Hasegawa, F; Komatsu, T; Nishio, K; Ochiya, T; Takeshita, F; Takigahira, M; Yanagihara, K | 1 |
Kudou, T; Munakata, M; Sakata, Y; Shitara, K | 1 |
Narahara, H; Sugimoto, N | 1 |
Asaka, M; Komatsu, Y; Miyagishima, T; Yuki, S | 1 |
Creemers, GJ; de Bruijn, P; de Jong, FA; de Jonge, MJ; Eskens, FA; Janssen, JT; Kehrer, DF; Mathijssen, RH; Planting, AS; Ruit, JB; Sparreboom, A; van der Gaast, A; van Schaik, RH; Verweij, J | 1 |
Boku, N; Fukutomi, A; Hironaka, S; Onozawa, Y; Ueda, S; Yoshino, T | 1 |
Kawamura, S; Okumura, S; Shimada, E; Sumi, Y; Tei, M; Yamagishi, D | 1 |
Fujiwara, T; Gouchi, A; Kagawa, S; Matsuoka, J; Nishizaki, M; Tanaka, N; Teraishi, F; Tokunaga, N; Uno, F | 1 |
Han, MJ; Kang, WK; Kim, HJ; Kwon, JM; Lee, HR; Lee, J; Lim, HY; Oh, SY; Park, BB; Park, JO; Park, YS | 1 |
Ishiguro, A; Kasai, M; Munakata, M; Sakata, Y; Shitara, K | 1 |
Fujitani, K; Furukawa, H; Ikeda, M; Imamoto, H; Imamura, H; Kato, M; Kobayashi, K; Narahara, H; Takabayashi, A; Tsujinaka, T; Tsukuma, H | 1 |
Capanu, M; D'Adamo, D; Ilson, DH; Kelsen, DP; Levnor, A; O'Reilly, E; Ramanathan, RK; Schwartz, GK; Schwartz, L; Shah, MA; Trocola, R; Tse, A | 1 |
Geng, M; Ji, YB; Jiang, JS; Li, H; Lou, GY; Ma, T; Xi, WQ; Xia, HQ; YeE, ZB | 1 |
Berardi, R; Cascinu, S; Ceccarelli, C; Di Fabio, F; Funaioli, C; Giannetta, L; Giaquinta, S; Longobardi, C; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL; Siena, S | 1 |
Arakawa, K; Hamada, K; Kashiwabara, K; Kawate, S; Morishita, Y; Ohwada, S; Sunose, Y; Takeyoshi, I; Tohgo, N; Toya, H; Tsutsumi, H | 1 |
Fujiwara, T; Gochi, A; Kagawa, S; Tanaka, N; Teraishi, F; Uno, F | 1 |
Hanada, M; Noguchi, T; Yamaoka, T | 1 |
Fujino, K; Ishikubo, T; Shimamura, T; Tada, M; Yamaguchi, K | 1 |
Akamaru, Y; Ito, A; Kasugai, T; Momiyama, T; Nakamura, Y; Ohse, N; Yamamoto, S; Yamasaki, Y; Yumiba, T | 1 |
Yoshida, S | 1 |
Matsukawa, M; Sato, A | 1 |
Fukushima, M; Hasegawa, S; Kawashima, K; Matsumoto, S; Nagayama, S; Nomura, A; Okabe, H; Sakai, Y; Satoh, S; Watanabe, G; Yoshibayashi, H | 1 |
López-Brea, MF; Rivera, F; Vega-Villegas, ME | 1 |
Aiba, K; Arai, K; Fujii, M; Hayashi, K; Ichikawa, W; Katsube, T; Kitajima, M; Kochi, M; Kubota, T; Ogawa, K; Takagi, Y; Terashima, M; Tokunaga, A | 1 |
Funada, R; Harada, K; Hasegawa, K; Homma, N; Ogata, N; Shibasaki, K; Soga, K; Uchida, M; Watanabe, T | 1 |
Hamano, R; Hirao, T; Kobayashi, T; Masuzawa, T; Shibata, K; Tokuoka, M | 1 |
Hasegawa, Y; Kataoka, Y; Kawamura, S; Kimura, H; Okumura, S; Shimada, E; Tei, M | 1 |
Choi, IK; Chun, HJ; Jeen, YT; Kim, JS; Kim, YH; Mok, YJ; Oh, SC; Park, SS; Seo, JH; Shin, SW; Sung, HJ; Sur, HY | 1 |
Hashimoto, H; Hirabayashi, T; Ishikawa, H; Ohi, S; Sugiyama, K; Tachibana, T; Takahashi, N; Yanaga, K | 1 |
Komatsu, N; Makuuchi, H; Matsui, N; Mukai, M; Nakamura, M; Nakasaki, H; Ninomiya, H; Sato, S; Wakui, K | 1 |
Inokuchi, M; Kawano, T; Kojima, K; Sekita, Y; Sugihara, K; Yamada, H; Yamashita, T | 1 |
Ae, T; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Saigenji, K; Sasaki, T; Tanabe, S | 1 |
Arai, H; Higashida, T; Imada, T; Kanari, M; Masuda, M; Nakayama, T; Rino, Y; Saeki, H; Sekino, Y; Wada, N; Yamada, T; Yukawa, N | 1 |
Kohno, H; Ogawa, A; Okajima, A; Taguchi, T; Takenouchi, Y; Tsugane, K | 1 |
Arena, MG; Di Lauro, L; Foggi, P; Lopez, M; Nunziata, C; Sperduti, I | 1 |
Sharma, SP | 1 |
Liu, MY; Luo, ZF; Zhou, Y | 1 |
Farhat, FS | 1 |
Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N | 1 |
Gotoh, M; Hashimoto, Y; Hoshino, Y; Kashimura, S; Kogure, M; Odashima, Y; Osuka, F; Otani, S; Saito, T; Saze, Z; Soeta, N; Terashima, M; Watanabe, K | 1 |
Kim, HJ; Kim, JH; Kim, SG; Kim, SH; Kwon, HC; Lee, S; Oh, SY | 1 |
Fujii, M; Hirota, M; Matsuda, C; Mikata, S; Morimoto, Y; Nishikawa, K; Tanaka, Y | 1 |
Meric, JB | 1 |
Moiseenko, VM; Volkov, NM | 1 |
Hirano, S; Kikuchi, Y; Kouzuma, T; Saito, T; Sato, T | 1 |
Ako, E; Kanemura, M; Kubo, N; Nishimura, S; Nobuhara, Y; Sunami, T; Yo, T | 1 |
Amadio, P; Caputo, G; Condorelli, S; Cordio, S; Germano, D; Manzione, L; Mattina, M; Reggiardo, G; Rosati, G | 1 |
Hanyu, F; Harada, N; Hayashi, T; Suzuki, M; Suzuki, S; Takeo, Y; Tanaka, S | 1 |
Nakano, T; Tomimatsu, H | 1 |
Cho, EK; Chung, M; Lee, JH; Lee, SI; Lee, WK; Nam, E; Park, J; Park, SH; Shin, DB | 1 |
Castellucci, P; Di Fabio, F; Fanti, S; Funaioli, C; Giaquinta, S; Longobardi, C; Martoni, AA; Mutri, V; Pinto, C; Rojas Llimpe, FL; Sperandi, F | 1 |
Doi, T; Handa, R; Hoshi, M; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Makari, Y; Miyake, Y; Oshima, K; Oshima, S | 1 |
Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohshiro, R; Ohta, K; Ohzato, H; Takemoto, H; Tatsuta, M | 1 |
Fujimi, S; Fukunaga, M; Furukawa, H; Imamura, H; Kamigaki, S; Kishimoto, T; Miyazaki, Y; Nakata, Y; Nakayama, T; Ohsato, H; Ohshiro, R; Ohta, K; Takemoto, H; Tatsuta, M | 1 |
Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G | 1 |
Hamaguchi, T; Kajiwara, T; Kato, K; Matsubara, J; Moriwaki, T; Nakajima, TE; Nishina, T; Oka, T; Okayama, Y; Shimada, Y; Shimoda, T; Shirao, K; Yamada, Y | 1 |
Kitagawa, Y; Kitajima, M; Kubota, T; Kumagai, K; Kumai, K; Nakamura, R; Saikawa, Y; Takahashi, T | 1 |
He, Q; Lu, W; Luo, Y; Weng, Q; Yang, B; Zhang, B | 1 |
Chang, HM; Kang, HJ; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Lee, SS; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH | 1 |
Belkhiri, A; Castells, A; Correa, P; Dar, AA; El-Rifai, W; Koyama, T; Pera, M; Piazuelo, MB; Washington, K; Zaika, A | 1 |
Fujitani, K; Furukawa, H; Goto, M; Hirao, M; Imano, M; Ishihara, R; Narahara, H; Taguchi, T; Takiuchi, H; Tsujinaka, T; Tsukuma, H; Uedo, N | 1 |
Carcereny, E; Casado, E; Fernández-Llamazares, J; Font, A; Gallego, R; Guix, M; Manzano, JL; Maurel, J; Ramirez, JL; Rosell, R; Salazar, R; Tabernero, J; Taron, M | 1 |
Chang, HM; Kang, YK; Kim, TW; Lee, JL; Lee, JS; Lee, SS; Ryu, MH; Sym, SJ | 1 |
Ajani, JA; Benson, AB; Evans, TR; Falk, S; Mena, RR; Mulcahy, MF; Picus, J; Scott, LC; Thomas, AL; Wright, J; Yao, JC | 1 |
Bouillet, T; Des Guetz, G; Morere, JF; Wind, P | 1 |
Hayashi, S; Karaki, H; Sugano, I; Sugimoto, K; Suzuki, H; Takayanagi, H; Yamamori, H; Yamamoto, K | 1 |
Fields, SZ; Hargis, JB; Lilenbaum, RC; Miller, AA; Rosner, GL; Schilsky, RL | 1 |
Akiyama, S; Andoh, T; Ito, K; Kodera, Y; Kondou, K; Nagai, S; Nishizawa, M; Satta, T; Takagi, H; Yamauchi, M | 1 |
Futatsuki, K; Kambe, M; Nakao, I; Ogawa, N; Sakata, Y; Shimada, Y; Taguchi, T; Wakui, A; Yoshino, M | 1 |
Cowan, KH; Fukuda, M; Ikeda, K; Kohno, S; Matsuo, I; Nakano, R; Narasaki, F; Oka, M; Soda, H; Takatani, H; Terashi, K; Tomonaga, M | 1 |
Boku, N; Fujii, T; Fukuda, H; Kondo, H; Muro, K; Oda, Y; Ohtsu, A; Oka, M; Ono, H; Saito, D; Shimada, Y; Shirao, K; Watanabe, Y; Yamao, T; Yokoyama, T; Yoshida, S | 1 |
Furue, H | 1 |
Harstrick, A; Kasimir-Bauer, S; Stahl, M | 1 |
Sakata, Y; Tsushima, K | 1 |
Araki, S; Asakura, R; Hojo, K; Itoh, A; Kawahara, M; Konishi, T; Nouchi, T; Takeda, Y; Teruya, M | 1 |
Jimbo, T; Kumazawa, E; Ochi, Y; Tohgo, A | 1 |
Ajani, JA | 1 |
Armand, JP; Couteau, C | 1 |
Fukuda, S; Kume, S; Nagamoto, N; Okamura, K; Sakaguchi, T; Tanabe, D | 1 |
Bleiberg, H | 1 |
Evers, BM; Hwang, KO; Kim, M; Litvak, DA; Papaconstantinou, HT; Townsend, CM | 1 |
Boku, N; Hyodo, I; Ohtsu, A; Saito, H; Sakata, Y; Seki, S; Shimada, Y; Shirao, K | 1 |
Kobayashi, A; Yamaguchi, M | 1 |
Eriguchi, M; Fujii, Y; Sairenji, T | 1 |
Handa, T; Kai, S; Kazami, A; Koizumi, K; Maruyama, M; Takemoto, N; Yamao, T | 1 |
Kobayashi, T; Maeda, Y; Okamoto, R; Omuro, Y; Sasaki, T; Takeda, N | 1 |
Baba, H; Endo, K; Ikeda, Y; Kohnoe, S; Nakashima, H; Okamura, T; Toh, Y | 1 |
Baba, H; Ebuchi, M; Kure, N; Maruyama, M; Nagahama, T; Toukairin, Y; Yoshida, T | 1 |
Ohtsu, A; Tahara, M | 1 |
Farthing, MJ; Patchett, SE; Zhang, ZW | 1 |
Köhne, CH; Wilke, HJ; Wils, JA | 1 |
Ajani, JA; Charnsangavej, C; Fairweather, J; Pisters, PW | 1 |
Ajani, JA; Blumenshein, GR; Fairweather, JS; Feig, BW; Ho, L; Janjan, NA; Komaki, R; Lynch, PM; Pazdur, R; Pisters, PW; Raijman, I; Walsh, GL | 1 |
Aida, K; Kikuchi, H; Kumada, K; Midorikawa, T; Nagasaki, H; Nemoto, H; Saito, M; Sanada, Y; Sasaya, S | 1 |
Ajani, JA; Baker, J; Feig, B; Ho, L; Mansfield, PF; Pisters, PW | 1 |
Mai, M; Takahashi, Y | 1 |
Koda, T; Kurihara, M; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Yamazaki, T | 1 |
Koda, T; Matsukawa, M; Nakamachi, M; Sato, A; Shimada, K; Wada, M | 1 |
Sakata, Y | 1 |
Hiratsuka, N; Sato, A; Tadokoro, K; Takebuchi, K; Ushio, J; Yamamoto, W | 1 |
Ando, M; Harada, Y; Koyanagi, Y; Maruyama, S; Ohnuma, S; Sakaniwa, N; Suzuki, K; Tadatomo, H; Tanaka, K; Yamashita, S | 1 |
Baba, H; Ebuchi, M; Kure, N; Maruyama, M; Nagahama, T; Toukairin, Y | 1 |
Boku, N; Muto, M; Nagashima, F; Ohtsu, A; Yoshida, M; Yoshida, S | 1 |
Wen, Z; Xiong, X; Zhu, Z | 1 |
Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML | 1 |
Chin, K; Goto, M; Matsumura, Y; Muro, K; Shimada, Y; Shirao, K; Yamada, Y; Yamao, T | 1 |
Aiba, K; Akaza, H; Blackledge, G; Boku, N; Ikeda, T; Isonishi, S; Kato, M; Kawai, K; Mikami, O; Ohashi, Y; Saeki, T; Saijo, N; Sone, S; Stribling, D; Tsukagoshi, S; Tsuruo, T | 1 |
Moertel, CG | 1 |
85 review(s) available for camptothecin and Cancer of Stomach
Article | Year |
---|---|
Trastuzumab deruxtecan and other HER2-targeting agents for the treatment of HER2-positive gastric cancer.
Topics: Camptothecin; Humans; Immunoconjugates; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2021 |
An overview of the preclinical discovery and development of trastuzumab deruxtecan: a novel gastric cancer therapeutic.
Topics: Camptothecin; Drug Therapy, Combination; Humans; Immunoconjugates; Stomach Neoplasms; Trastuzumab | 2022 |
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Lung Neoplasms; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2019 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Trastuzumab deruxtecan for the treatment of HER2-positive advanced gastric cancer: a clinical perspective.
Topics: Camptothecin; Disease-Free Survival; Humans; Immunoconjugates; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2021 |
Trastuzumab deruxtecan for the treatment of HER2-positive gastric cancer.
Topics: Camptothecin; Humans; Immunoconjugates; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2021 |
Discovery and development of trastuzumab deruxtecan and safety management for patients with HER2-positive gastric cancer.
Topics: Camptothecin; Drug Development; Drug Monitoring; Drug-Related Side Effects and Adverse Reactions; Humans; Immunoconjugates; Lung Diseases, Interstitial; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2021 |
Harnessing biomarkers of response to improve therapy selection in esophago-gastric adenocarcinoma.
Topics: Adenocarcinoma; Biomarkers; Biomarkers, Tumor; Camptothecin; Esophageal Neoplasms; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy; Precision Medicine; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2021 |
The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Platinum Compounds; Ramucirumab; Stomach Neoplasms; Taxoids; Trastuzumab; Treatment Outcome | 2017 |
[Long-Term Survival of a Gastric Neuroendocrine Carcinoma Patient with Extra-Regional Lymph Node Metastases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Recurrence; Stomach Neoplasms; Time Factors | 2017 |
Chemotherapy for advanced gastric cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Fluorouracil; Humans; Irinotecan; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2017 |
Irinotecan-containing doublet treatment versus irinotecan monotherapy as second-line choice for advanced gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Humans; Irinotecan; Stomach Neoplasms; Treatment Outcome | 2018 |
Overview of adjuvant and neoadjuvant therapy for resectable gastric cancer in the East.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia, Eastern; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Evidence-Based Medicine; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2013 |
Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials, Phase III as Topic; Docetaxel; Fluorouracil; Humans; Irinotecan; Neoplasm Recurrence, Local; Neoplasm Staging; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2013 |
Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Failure; Treatment Outcome; Young Adult | 2014 |
Chemotherapy with or without irinotecan in patients with advanced or recurrent gastric cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Irinotecan; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2014 |
[Case report of chemotherapeutic control of a gastric cancer producing granulocyte-colony stimulating factor].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fatal Outcome; Gastroscopy; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2014 |
Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Patient Selection; Stomach Neoplasms; Taxoids; Treatment Outcome | 2014 |
[A case of gastric small cell carcinoma with liver and lymph node metastases responding to CPT-11 plus CDDP chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Stomach Neoplasms; Treatment Outcome | 2014 |
[CURRENT STATE OF ADJUVANT TREATMENT FOR GASTRIC CANCER AFTER RADICAL SURGERY WITH EXTENDED LYMPH NODE DISSECTION].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Gastrectomy; Humans; Leucovorin; Lymph Node Excision; Multicenter Studies as Topic; Oxaloacetates; Oxonic Acid; Paclitaxel; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Tegafur; Treatment Outcome | 2015 |
Capecitabine for the treatment of gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2015 |
Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Asian People; Camptothecin; Docetaxel; Humans; Irinotecan; Neoplasm Staging; Pyridines; Ramucirumab; Stomach Neoplasms; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
An Integrative Approach to Precision Cancer Medicine Using Patient-Derived Xenografts.
Topics: Animals; Antineoplastic Agents; Biomarkers, Pharmacological; Biphenyl Compounds; Camptothecin; Drug Synergism; Graft Survival; Humans; Irinotecan; Mice; Mice, Nude; Mice, SCID; Molecular Targeted Therapy; Nitrophenols; Piperazines; Precision Medicine; Stomach Neoplasms; Sulfonamides; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Irinotecan; Neoplasm Staging; Proportional Hazards Models; Publication Bias; Retreatment; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2017 |
The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Capecitabine; Cisplatin; Disease-Free Survival; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Methotrexate; Network Meta-Analysis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2016 |
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; ErbB Receptors; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Radiation-Sensitizing Agents; Stomach Neoplasms; Taxoids; Tegafur; Vascular Endothelial Growth Factor A | 2008 |
The role of capecitabine in the management of tumors of the digestive system.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Cholangiocarcinoma; Colonic Neoplasms; Deoxycytidine; Digestive System Neoplasms; Docetaxel; Esophageal Neoplasms; Fluorouracil; Gallbladder Neoplasms; Humans; Irinotecan; Liver Neoplasms; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Is there a role for second-line chemotherapy in advanced gastric cancer?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Platinum Compounds; Salvage Therapy; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors | 2009 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
[Histological complete response in a case of advanced gastric endocrine carcinoma treated by irinotecan plus cisplatin].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Humans; Irinotecan; Male; Stomach Neoplasms | 2009 |
Chemotherapy for advanced gastric cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Fluorouracil; Humans; Irinotecan; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids | 2010 |
Role of capecitabine and irinotecan combination therapy in advanced or metastatic gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Topic; Deoxycytidine; Drug Design; Fluorouracil; Humans; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2010 |
[Metastatic gastric cancer: does second-line chemotherapy make sense?].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Irinotecan; Neoplasm Staging; Palliative Care; Practice Guidelines as Topic; Quality of Life; Randomized Controlled Trials as Topic; Retreatment; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
Irinotecan-involved regimens for advanced gastric cancer: a pooled-analysis of clinical trials.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Drug Therapy, Combination; Humans; Irinotecan; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate | 2010 |
[A case of recurrent gastric cancer with lymph node metastasis successfully treated by CPT-11/CDDP therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Remission Induction; Salvage Therapy; Stomach Neoplasms | 2011 |
[A case of gastric neuroendocrine cell carcinoma successfully treated by neoadjuvant chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Male; Neoadjuvant Therapy; Stomach Neoplasms | 2011 |
Second-line chemotherapy for advanced gastric cancer in Korea.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Disease-Free Survival; Fluorouracil; Humans; Irinotecan; Republic of Korea; Stomach Neoplasms; Taxoids | 2012 |
Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: an updated meta-analysis of ten randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Humans; Induction Chemotherapy; Irinotecan; Proportional Hazards Models; Randomized Controlled Trials as Topic; Stomach Neoplasms; Treatment Outcome | 2013 |
Chemotherapeutic options for gastroesophageal junction tumors.
Topics: Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Palliative Care; Stomach Neoplasms; Taxoids | 2013 |
Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction.
Topics: Amiodarone; Anti-Arrhythmia Agents; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Coronary Angiography; Diagnostic Errors; Docetaxel; Electric Countershock; Fatal Outcome; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Myocardial Infarction; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Takotsubo Cardiomyopathy; Taxoids; Ventricular Fibrillation | 2013 |
[A case of AFP-producing gastric cancer with multiple liver metastases responding to CPT-11 and cisplatin combination chemotherapy].
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms | 2002 |
Irinotecan in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2003 |
Current treatments and future perspectives in colorectal and gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Radiotherapy, Adjuvant; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
[Recent advances in chemotherapy for digestive cancers with special references to gastric and colonic cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colonic Neoplasms; Docetaxel; Drug Administration Schedule; Drug Combinations; Drug Delivery Systems; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2003 |
[Controversial issues in chemotherapy for inoperable gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur | 2003 |
[Chemotherapy for gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Meta-Analysis as Topic; Neoadjuvant Therapy; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2003 |
Focus on gastric cancer.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cadherins; Camptothecin; Carcinogens; Docetaxel; Fluorouracil; Gerbillinae; Herpesvirus 4, Human; Humans; Irinotecan; Lymphatic Metastasis; Mice; Mice, Transgenic; Models, Animal; Mutation; Neoplasm Staging; Neoplasms, Experimental; Rats; Stomach Neoplasms; Taxoids | 2004 |
[A case of gastric metastasis of small cell cancer of the lung, regression of the gastric lesion after chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Fatal Outcome; Gastroscopy; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Staging; Stomach Neoplasms | 2004 |
Chemotherapy in gastric cancer: a brief chronicle with emphasis on recent developments.
Topics: Antineoplastic Agents; Camptothecin; Carcinoma; Chemotherapy, Adjuvant; Docetaxel; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pyrimidines; Stomach Neoplasms; Taxoids | 2004 |
Pharmacogenomics and stomach cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Humans; Irinotecan; Pharmacogenetics; Stomach Neoplasms; Taxoids | 2004 |
Palliative chemotherapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Epirubicin; Fluorouracil; Humans; Irinotecan; Palliative Care; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Treatment Outcome | 2004 |
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2004 |
[CPT-11 combined chemotherapy for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Mitomycin; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2004 |
[Chemotherapy of advanced stomach cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2004 |
Perioperative adjunctive treatment in the management of operable gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans; Irinotecan; Leucovorin; Preoperative Care; Radiotherapy Dosage; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Stomach Neoplasms | 2005 |
Gastric cancer. Treatment of advanced disease and new drugs.
Topics: Antineoplastic Agents; Camptothecin; Docetaxel; Drug Therapy; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids | 2005 |
Experience with docetaxel in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Gemcitabine; Humans; Irinotecan; Stomach Neoplasms; Taxoids | 2005 |
[Molecular biology in clinical cancer research: the example of digestive cancers].
Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomedical Research; Camptothecin; Chromosomal Instability; Chromosomes, Human, 16-18; Chromosomes, Human, 21-22 and Y; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 8; Clinical Trials as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; DNA, Neoplasm; Fluorouracil; Forecasting; Genes, Tumor Suppressor; Genetic Markers; Humans; Immunohistochemistry; Irinotecan; Molecular Biology; Multivariate Analysis; Mutation; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenotype; Prognosis; Stomach Neoplasms | 2005 |
Determinants of chemosensitivity in gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Clinical Trials as Topic; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Drug Resistance, Neoplasm; Endonucleases; Fluorouracil; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Glutathione S-Transferase pi; Humans; Irinotecan; Mutation; Organoplatinum Compounds; Polymorphism, Genetic; Stomach Neoplasms; Taxoids; Thymidylate Synthase; Treatment Outcome; Xeroderma Pigmentosum Group D Protein | 2006 |
[S-1 for gastric cancer-S-1 monotherapy and its progress].
Topics: Administration, Oral; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Leukopenia; Neutropenia; Oxonic Acid; Quality of Life; Stomach Neoplasms; Stomatitis; Tegafur | 2006 |
[Combination chemotherapy of S-1 +CPT-11 (q 4-5 w) for metastatic gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Metastasis; Oxonic Acid; Stomach Neoplasms; Tegafur | 2006 |
[Chemotherapy in advanced gastric cancer--to ensure timely and appropriate switch to subsequent treatment options].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Leucovorin; Methotrexate; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2007 |
[Basic strategies on first- and second-line chemotherapy for advanced gastric cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Survival Rate; Taxoids | 2007 |
[Clinical development of chemotherapy for advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2007 |
Chemotherapy of advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 2007 |
A general review of the role of irinotecan (CPT11) in the treatment of gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Drug Administration Routes; Drug Administration Schedule; Humans; Irinotecan; Neoadjuvant Therapy; Prognosis; Stomach Neoplasms | 2007 |
[Angiogenesis targeting in gastro-intestinal cancers].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Hepatocellular; Colorectal Neoplasms; Esophageal Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2007 |
[Drug therapy for inoperable gastric cancer: current possibilities and perspectives of development].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Humans; Platinum Compounds; Randomized Controlled Trials as Topic; Research Design; Stomach Neoplasms; Taxoids | 2007 |
Chemotherapy for gastric cancer in Japan.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Stomach Neoplasms | 1997 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Methotrexate; Mitomycin; Neoplastic Cells, Circulating; Peritoneal Neoplasms; Stomach Neoplasms | 1998 |
[Chemotherapy of gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Methotrexate; Stomach Neoplasms | 1998 |
Chemotherapy for gastric carcinoma: new and old options.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Capecitabine; Deoxycytidine; Docetaxel; Drug Combinations; Enzyme Inhibitors; Etoposide; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur; Uracil | 1998 |
[Irinotecan-containing combinations in solid tumors, except colonic carcinomas].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Docetaxel; Enzyme Inhibitors; Etoposide; Female; Genital Neoplasms, Female; Humans; Irinotecan; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Neoplasm Proteins; Neoplasms; Neutropenia; Paclitaxel; Stomach Neoplasms; Taxoids; Topoisomerase I Inhibitors; Treatment Outcome | 1998 |
CPT-11 in gastrointestinal cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Humans; Irinotecan; Pancreatic Neoplasms; Stomach Neoplasms | 1999 |
[New combination therapies for gastrointestinal cancer].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Docetaxel; Fluorouracil; Humans; Irinotecan; Leucovorin; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
[State of the treatment for gastrointestinal cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Doxorubicin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Mitomycin; Stomach Neoplasms | 2000 |
[Latest progress on chemotherapy for advanced gastric cancer].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Oxonic Acid; Paclitaxel; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur | 2000 |
Developments in the treatment of gastric cancer in Europe.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Docetaxel; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Neoplasm Metastasis; Paclitaxel; Randomized Controlled Trials as Topic; Stomach Neoplasms; Survival Analysis; Taxoids | 2000 |
Irinotecan and cisplatin in advanced gastric or gastroesophageal junction carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials, Phase II as Topic; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Stomach Neoplasms | 2000 |
Phase I study of irinotecan and concurrent radiation therapy for upper GI tumors.
Topics: Adolescent; Antineoplastic Agents, Phytogenic; Camptothecin; Clinical Trials, Phase I as Topic; Esophageal Neoplasms; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Staging; Radiation Dosage; Radiotherapy, Adjuvant; Stomach Neoplasms | 2000 |
Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Stomach Neoplasms | 2001 |
[Chemotherapy of irinotecan (CPT-11) combined with cisplatin in patients with advanced gastric cancer].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Clinical Trials as Topic; Humans; Irinotecan; Neoplasm Staging; Stomach Neoplasms | 2001 |
[Irinotecan (CPT-11) therapy for advanced gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Clinical Trials, Phase II as Topic; Humans; Irinotecan; Mitomycin; Stomach Neoplasms; Topoisomerase I Inhibitors; Treatment Outcome | 2001 |
[Home chemotherapy and/or outpatient chemotherapy for patient with advanced gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Endpoint Determination; Fluorouracil; Home Infusion Therapy; Humans; Irinotecan; Quality of Life; Stomach Neoplasms | 2001 |
157 trial(s) available for camptothecin and Cancer of Stomach
Article | Year |
---|---|
Safety and efficacy profile of Trastuzumab deruxtecan in solid cancer: pooled reanalysis based on clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Breast Neoplasms; Camptothecin; Female; Humans; Immunoconjugates; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2022 |
Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Male; Markov Chains; Middle Aged; Organoplatinum Compounds; Quality-Adjusted Life Years; Stomach Neoplasms; Treatment Outcome; Young Adult | 2020 |
Nivolumab in Combination with Irinotecan and 5-Fluorouracil (FOLFIRI) for Refractory Advanced Gastroesophageal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Nivolumab; Prognosis; Progression-Free Survival; Retrospective Studies; Stomach Neoplasms | 2020 |
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Marrow; Camptothecin; Esophageal Neoplasms; Female; Humans; Immunoconjugates; Irinotecan; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Receptor, ErbB-2; Stomach Neoplasms; Survival Analysis; Trastuzumab | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; France; Humans; Leucovorin; Male; Stomach Neoplasms; Treatment Outcome | 2021 |
Effect of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Women: A Randomized Clinical Trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Camptothecin; China; Double-Blind Method; Female; Fluorouracil; Humans; Leucovorin; Middle Aged; Nausea; Organoplatinum Compounds; Stomach Neoplasms; Vomiting | 2021 |
Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Capecitabine; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorodeoxyglucose F18; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Positron Emission Tomography Computed Tomography; Postoperative Care; Preoperative Care; Stomach Neoplasms | 2017 |
Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients - AGMT_GASTRIC-3.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Camptothecin; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2017 |
Genomic predictors of chemotherapy efficacy in advanced or recurrent gastric cancer in the GC0301/TOP002 phase III clinical trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Wnt-5a Protein | 2018 |
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Carcinoma, Neuroendocrine; Drug Administration Schedule; Female; Fluorouracil; France; Humans; Intestinal Neoplasms; Leucovorin; Male; Neuroendocrine Tumors; Pancreatic Neoplasms; Research Design; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2018 |
Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Indoles; Keratin-18; Leucovorin; Male; Middle Aged; Peptide Fragments; Placebos; Pyrroles; Stomach Neoplasms; Sunitinib | 2018 |
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Prognosis; Ramucirumab; Stomach Neoplasms; Survival Rate | 2019 |
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Camptothecin; Female; Follow-Up Studies; Humans; Immunoconjugates; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Receptor, ErbB-2; Salvage Therapy; Stomach Neoplasms; Survival Rate; Tissue Distribution; Trastuzumab | 2019 |
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Camptothecin; Docetaxel; Drug Carriers; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Nanocapsules; Stomach Neoplasms; Survival Rate; Taxoids | 2013 |
Preoperative cetuximab, irinotecan, cisplatin, and radiation therapy for patients with locally advanced esophageal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemoradiotherapy, Adjuvant; Cisplatin; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Prospective Studies; Stomach Neoplasms; Young Adult | 2013 |
Phase II study on pemetrexed-based chemotherapy in treating patients with metastatic gastric cancer not responding to prior palliative chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Glutamates; Guanine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Organoplatinum Compounds; Pemetrexed; Stomach Neoplasms; Treatment Outcome | 2013 |
A phase II trial of trastuzumab combined with irinotecan in patients with advanced HER2-positive chemo-refractory gastric cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group OGSG1203 (HERBIS-5).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Patient Selection; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2013 |
CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Combinations; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2013 |
Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Dihydrouracil Dehydrogenase (NADP); DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Fluorouracil; Gene Expression; Humans; Irinotecan; Male; Oxonic Acid; Prognosis; RNA, Messenger; Stomach Neoplasms; Survival; Tegafur; Thymidylate Synthase; Vascular Endothelial Growth Factor A | 2013 |
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Camptothecin; Cohort Studies; Colorectal Neoplasms; Cytochrome P-450 CYP2A6; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Half-Life; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Survival Analysis; Tegafur | 2013 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Paclitaxel; Platinum; Prospective Studies; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Stratified phase II trial to establish the usefulness of the collagen gel droplet embedded culture-drug sensitivity test (CD-DST) for advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Collagen; Docetaxel; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Dose Fractionation, Radiation; Feasibility Studies; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Postoperative Period; Preoperative Period; Stomach; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Randomized phase II trial of S-1 plus irinotecan versus S-1 plus paclitaxel as first-line treatment for advanced gastric cancer (OGSG0402).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Prospective Studies; Stomach Neoplasms; Tegafur | 2014 |
Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Camptothecin; Esophageal Neoplasms; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Proteasome Inhibitors; Pyrazines; Stomach Neoplasms | 2014 |
Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Creatinine; Disease-Free Survival; Female; Humans; Irinotecan; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2014 |
Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin).
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2014 |
Determination of prognostic factors in Japanese patients with advanced gastric cancer using the data from a randomized controlled trial, Japan clinical oncology group 9912.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Japan; Male; Neoplasm Metastasis; Prognosis; Risk Factors; Stomach Neoplasms | 2014 |
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Leukopenia; Lymphatic Metastasis; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Prospective Studies; Recurrence; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2014 |
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Humans; Leucovorin; Stomach Neoplasms; Taxoids | 2014 |
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Cancer, Regional Perfusion; Female; Fluorouracil; Gastrectomy; Humans; Hyperthermia, Induced; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Stomach Neoplasms | 2014 |
Further study on pemetrexed based chemotherapy in treating patients with advanced gastric cancer (AGC).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Folic Acid Antagonists; Glutamates; Guanine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Pemetrexed; Stomach Neoplasms; Treatment Outcome | 2014 |
Randomized phase II trial of nimotuzumab plus irinotecan versus irinotecan alone as second-line therapy for patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Genes, ras; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Polymerase Chain Reaction; Receptor, ErbB-2; Salvage Therapy; Stomach Neoplasms; Treatment Outcome | 2015 |
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; France; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Prospective Studies; Quality of Life; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2014 |
Randomised phase III trial of second-line irinotecan plus cisplatin versus irinotecan alone in patients with advanced gastric cancer refractory to S-1 monotherapy: TRICS trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Disease Progression; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Failure | 2015 |
A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Paclitaxel; Stomach Neoplasms | 2015 |
Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2015 |
Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regime
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2016 |
Phase II and UGT1A1 Polymorphism Study of Two Different Irinotecan Dosages Combined with Cisplatin as First-Line Therapy for Advanced Gastric Cancer.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Cisplatin; Drug Dosage Calculations; Drug Therapy, Combination; Female; Gene Frequency; Genotype; Glucuronosyltransferase; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Single Nucleotide; Stomach Neoplasms; Tomography, X-Ray Computed | 2016 |
Molecular Biomarker Study in a Randomised Phase III Trial of Irinotecan Plus S-1 versus S-1 for Advanced Gastric Cancer (GC0301/TOP-002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Dihydrouracil Dehydrogenase (NADP); DNA Topoisomerases, Type I; DNA-Binding Proteins; Drug Combinations; Endonucleases; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Prognosis; Retrospective Studies; RNA, Messenger; Stomach Neoplasms; Tegafur; Thymidine Phosphorylase; Thymidylate Synthase | 2016 |
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Disease-Free Survival; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Esophageal Neoplasms; Female; Fluorouracil; Humans; Indoles; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Pyrroles; Stomach Neoplasms; Sunitinib | 2016 |
Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Camptothecin; Cisplatin; Female; Humans; Induction Chemotherapy; Intestinal Neoplasms; Irinotecan; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2017 |
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms | 2008 |
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Disease Progression; Dose-Response Relationship, Drug; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Prognosis; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2009 |
Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Patient Selection; Proportional Hazards Models; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival in selected patients with peritoneal carcinomatosis from abdominal and pelvic malignancies: results of 21 cases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Male; Mesothelioma; Middle Aged; Mitomycin; Ovarian Neoplasms; Peritoneal Neoplasms; Prognosis; Stomach Neoplasms; Survival Rate | 2009 |
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2009 |
Weekly docetaxel, cisplatin, and irinotecan (TPC): results of a multicenter phase II trial in patients with metastatic esophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids | 2009 |
Phase II trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) as first-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Humans; Infusions, Intravenous; Leucovorin; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Magnetic Resonance Imaging; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Tomography, X-Ray Computed | 2009 |
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Digestive System Neoplasms; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pancreatic Neoplasms; Quality of Life; Stomach Neoplasms; Taxoids; Treatment Outcome; Vitamin B Complex | 2010 |
Phase I study of weekly cisplatin, bolus fluorouracil and escalating doses of irinotecan in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Digestive System Neoplasms; Disease Progression; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Time Factors; Treatment Outcome | 2009 |
Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; DNA-Binding Proteins; Endonucleases; Female; Fluorouracil; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Gene Frequency; Genotype; Glucuronosyltransferase; Glutathione Transferase; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Patient Selection; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Predictive Value of Tests; Stomach Neoplasms; Thymidylate Synthase; Time Factors; Treatment Outcome | 2009 |
Phase II trial of preoperative irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for resectable locally advanced gastric and esophagogastric junction adenocarcinoma.
Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Preoperative Period; Prospective Studies; Remission Induction; Spain; Stomach Neoplasms; Survival Rate | 2009 |
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Leucovorin; Middle Aged; Neoplasm Metastasis; Palliative Care; Quality of Life; Stomach Neoplasms; Young Adult | 2009 |
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms | 2010 |
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Radiotherapy, Adjuvant; Stomach Neoplasms | 2010 |
Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Epidemiologic Methods; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2009 |
[Combination of irinotecan and Mitomycin C as second-line chemotherapy for patients with unresectable advanced or recurrent gastric cancer in clinical practice].
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2009 |
A phase II study of a combined biweekly irinotecan and monthly cisplatin treatment for metastatic or recurrent gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Female; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
[Clinical effects of Hange-shashin-to on combination therapy of S-1/irinotecan against the for patients with metastatic gastric and colorectal cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Combinations; Drugs, Chinese Herbal; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Quality of Life; Stomach Neoplasms; Tegafur | 2009 |
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Gastrectomy; Gastrointestinal Diseases; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Treatment Outcome | 2010 |
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Male; Middle Aged; Oxonic Acid; Proportional Hazards Models; Risk Assessment; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome; Young Adult | 2009 |
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Hyperthermia, Induced; Leucovorin; Organoplatinum Compounds; Peritoneum; Pneumonectomy; Stomach Neoplasms; Survival Rate | 2009 |
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
Phase II trial of induction irinotecan-cisplatin followed by concurrent irinotecan-cisplatin and radiotherapy for unresectable, locally advanced gastric and oesophageal-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Esophagogastric Junction; Follow-Up Studies; Humans; Irinotecan; Stomach Neoplasms; Survival Rate | 2011 |
Irinotecan hydrochloride (CPT-11) in dialysis patients with gastrointestinal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Female; Gastrointestinal Neoplasms; Humans; Irinotecan; Kidney Failure, Chronic; Leukopenia; Male; Middle Aged; Rectal Neoplasms; Renal Dialysis; Stomach Neoplasms | 2010 |
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Polyethylene Glycols; Recombinant Proteins; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
Phase I study of intraperitoneal irinotecan in patients with gastric adenocarcinoma with peritoneal seeding.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Fever; Follow-Up Studies; Gastrectomy; Humans; Infusions, Parenteral; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Peritoneal Dialysis, Continuous Ambulatory; Peritoneal Neoplasms; Stomach Neoplasms | 2011 |
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Taxoids; Treatment Outcome | 2010 |
Phase II randomized study of two regimens of sequentially administered mitomycin C and irinotecan in patients with unresectable esophageal and gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Squamous Cell; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2010 |
Phase 1/2 clinical study of irinotecan and oral S-1 (IRIS) in patients with advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur; Young Adult | 2010 |
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Statistics as Topic; Stomach Neoplasms; Surveys and Questionnaires; Survival Analysis; Taxoids; Time Factors; Vitamin B Complex | 2010 |
Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Polymorphism, Genetic; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2010 |
Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2011 |
Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Survival; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Oxonic Acid; Patient Selection; Salvage Therapy; Serum Albumin; Stomach Neoplasms; Survival; Tegafur; Treatment Outcome | 2011 |
Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as first-line treatment for advanced gastric cancer (study GC0301/TOP-002).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Drug Combinations; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2011 |
Closed abdomen hyperthermic intraperitoneal chemotherapy with irinotecan and mitomycin C: a phase I study.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hyperthermia, Induced; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2011 |
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Japan; Male; Methotrexate; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II trial of first-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301).
Topics: Adult; Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Camptothecin; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome; Young Adult | 2011 |
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuritis; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Remission Induction; Stomach Neoplasms; Young Adult | 2011 |
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Female; Germany; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Palliative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2011 |
[Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer].
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2011 |
Evaluation of efficacy and safety of FOLFIRI for elderly patients with gastric cancer: a first-line phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Stomach Neoplasms | 2011 |
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms | 2011 |
Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT).
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cetuximab; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2011 |
FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Pilot Projects; Prospective Studies; Stomach Neoplasms | 2011 |
Phase II study of biweekly cetuximab in combination with irinotecan as second-line treatment in patients with platinum-resistant gastro-oesophageal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Chemotherapy, Adjuvant; Drug Administration Schedule; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Stomach Neoplasms; Survival Analysis | 2012 |
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Platinum Compounds; Proportional Hazards Models; Prospective Studies; Pyrimidines; Republic of Korea; Risk Assessment; Risk Factors; Salvage Therapy; Stomach Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2012 |
Phase II and UGT1A1 genotype study of irinotecan dose escalation as salvage therapy for advanced gastric cancer.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms | 2012 |
Docetaxel combined with irinotecan or 5-fluorouracil in patients with advanced oesophago-gastric cancer: a randomised phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Taxoids | 2012 |
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2013 |
Phase II trial of cetuximab plus cisplatin and irinotecan in patients with cisplatin and irinotecan-refractory metastatic esophagogastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2014 |
Irinotecan/cisplatin in advanced, treated gastric or gastroesophageal junction carcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Survival Rate | 2002 |
Chronomodulated chemotherapy in metastatic gastrointestinal cancer combining 5-FU and sodium folinate with oxaliplatin, irinotecan or gemcitabine: the Jena experience in 79 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Camptothecin; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Folic Acid; Gastrointestinal Neoplasms; Gemcitabine; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Stomach Neoplasms | 2002 |
[Clinical study on patients with advanced gastric cancer treated with oxaliplatin combining with hydroxycamptothecine].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2002 |
A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Docetaxel; Dose-Response Relationship, Drug; Esophageal Neoplasms; Female; Humans; Hypotension; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Nausea; Paclitaxel; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2002 |
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Square Distribution; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Odds Ratio; Probability; Risk Assessment; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2003 |
Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease Progression; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Weekly treatment with irinotecan, folinic acid and infusional 5-fluorouracil (ILF) in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Pilot Projects; Prospective Studies; Stomach Neoplasms | 2003 |
Biweekly administration regimen of docetaxel combined with CPT-11 in patients with inoperable or recurrent gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Taxoids | 2003 |
Phase I study of irinotecan and S-1 combination therapy in patients with metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Fatigue; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2003 |
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Treatment Outcome | 2004 |
Pilot study of low-dose, divided maximum tolerated dose of CPT-11 in 21 consecutive patients with metastatic colorectal or gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Disease Progression; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Pilot Projects; Stomach Neoplasms | 2004 |
Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Treatment Failure; Treatment Outcome | 2004 |
9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Camptothecin; Esophageal Neoplasms; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2004 |
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2004 |
A randomized phase II clinical trial of tailored CPT-11 + S-1 vs S-1 in patients with advanced or recurrent gastric carcinoma as the first line chemotherapy.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie
Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; France; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Survival Analysis; Survival Rate; Treatment Outcome | 2004 |
[A randomized phase II clinical trial of tailored CPT-11 + TS-1 vs TS-1 in patients with advanced or recurrent gastric carcinoma as the first-line chemotherapy (JFMC31-0301)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Maximum Tolerated Dose; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Randomized Controlled Trials as Topic; Stomach Neoplasms; Tegafur | 2004 |
Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Humans; Incidence; Irinotecan; Risk Factors; Stomach Neoplasms; Thromboembolism; Thrombophilia | 2005 |
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Remission Induction; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Etoposide; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Levoleucovorin; Male; Middle Aged; Neoplasm Staging; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Irinotecan plus cisplatin combination against metastatic gastric cancer: phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2005 |
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Stomach Neoplasms; Treatment Outcome | 2005 |
Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced gastric cancer (OGSG 0002).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Pyridines; Stomach Neoplasms; Survival Rate; Tegafur; Treatment Outcome | 2005 |
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Humans; Irinotecan; Italy; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neutropenia; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
Biweekly irinotecan and cisplatin as second-line chemotherapy in pretreated patients with advanced gastric cancer: a multicenter phase II study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms | 2005 |
Neoadjuvant chemotherapy, surgery, and adjuvant intraperitoneal chemotherapy in patients with locally advanced gastric or gastroesophageal junction carcinoma: a phase II study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Esophagectomy; Esophagogastric Junction; Female; Floxuridine; Gastrectomy; Humans; Infusions, Parenteral; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms; Treatment Outcome | 2005 |
A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Follow-Up Studies; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Palliative Care; Prospective Studies; Stomach Neoplasms; Survival Analysis; Terminally Ill; Treatment Outcome | 2005 |
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Health Status; Humans; Irinotecan; Leucovorin; Longitudinal Studies; Male; Middle Aged; Quality of Life; Stomach Neoplasms; Survival Analysis | 2005 |
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Female; Humans; Injections, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Oxonic Acid; Safety; Stomach Neoplasms; Survival Rate; Tegafur; Time Factors; Treatment Outcome | 2006 |
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Drug Administration Schedule; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2006 |
Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate; Taxoids | 2006 |
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
A phase II trial of weekly fractionated irinotecan and cisplatin for advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Outpatients; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2007 |
[Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capsules; Diarrhea; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intravenous; Irinotecan; Middle Aged; Nausea; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2006 |
Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Colorectal Neoplasms; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Mass Screening; Middle Aged; Neomycin; Placebos; Stomach Neoplasms | 2006 |
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Disease Progression; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Prospective Studies; Stomach Neoplasms; Survival Rate; Time Factors; Treatment Outcome | 2007 |
Phase II study of protracted irinotecan infusion and a low-dose cisplatin for metastatic gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2006 |
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Italy; Kaplan-Meier Estimate; Karnofsky Performance Status; Leucovorin; Male; Middle Aged; Positron-Emission Tomography; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Phase I/II study of irinotecan (CPT-11) and S-1 in the treatment of advanced gastric cancer.
Topics: Adult; Aged; Antiemetics; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Analysis; Tegafur | 2007 |
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome | 2007 |
[Second-line chemotherapy in gastric cancer following S-1 with CPT-11 chemotherapy performed as clinical trial].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
Irinotecan, docetaxel and oxaliplatin combination in metastatic gastric or gastroesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease Progression; Docetaxel; Esophagogastric Junction; Female; Fever; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Taxoids; Treatment Outcome; Vomiting | 2007 |
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Digestive System Surgical Procedures; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Feasibility Studies; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Mitomycin; Neutropenia; Prospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Thrombocytopenia; Treatment Outcome | 2006 |
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Leucovorin; Male; Middle Aged; Nausea; Salvage Therapy; Stomach Neoplasms; Stomatitis; Survival Rate; Treatment Outcome | 2007 |
Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Treatment Outcome | 2007 |
Randomized phase II study of irinotecan, leucovorin and 5-fluorouracil (ILF) versus cisplatin plus ILF (PILF) combination chemotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Quality of Life; Stomach Neoplasms; Surveys and Questionnaires; Treatment Outcome | 2008 |
Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2007 |
A phase II study of irinotecan and docetaxel combination chemotherapy for patients with previously treated metastatic or recurrent advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Disease Progression; Docetaxel; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Irinotecan; Male; Middle Aged; Remission Induction; Stomach Neoplasms; Survival Analysis; Taxoids | 2008 |
Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002).
Topics: Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome | 2007 |
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease Progression; Disease-Free Survival; DNA Repair; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Polymorphism, Single Nucleotide; Stomach Neoplasms; Survival Analysis; Taxoids; Xeroderma Pigmentosum Group D Protein | 2008 |
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Esophagogastric Junction; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Polyethylene Glycols; Quality of Life; Stomach Neoplasms; Treatment Outcome | 2009 |
Phase I study of topotecan and cisplatin in patients with advanced solid tumors: a cancer and leukemia group B study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Neutropenia; Recombinant Proteins; Salivary Gland Neoplasms; Stomach Neoplasms; Topotecan | 1994 |
[Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Irinotecan; Leukopenia; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms | 1994 |
Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Male; Middle Aged; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Thrombocytopenia | 1997 |
Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms; Survival Rate | 1999 |
[Preliminary clinical comparison of HLF and ELF regimen in the treatment of advanced gastric carcinoma in middle-aged and elderly patients].
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Etoposide; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms | 2000 |
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2001 |
Phase I-II study of irinotecan combined with mitomycin-C in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Diarrhea; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Mitomycin; Neoplasm Staging; Neutropenia; Stomach Neoplasms; Survival Rate; Thrombocytopenia | 2001 |
CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Fatigue; Female; Humans; Irinotecan; Male; Middle Aged; Neutropenia; Stomach Neoplasms; Treatment Outcome | 2002 |
321 other study(ies) available for camptothecin and Cancer of Stomach
Article | Year |
---|---|
Design, synthesis and bioactivity evaluation of novel evodiamine derivatives with excellent potency against gastric cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Proliferation; Cells, Cultured; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship | 2022 |
Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing?
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Young Adult | 2022 |
Dramatic Response to Trastuzumab Deruxtecan Rechallenge in a Patient with HER2-Positive Gastric Cancer: A Case Report.
Topics: Aged; Camptothecin; Humans; Immunoconjugates; Male; Stomach Neoplasms; Trastuzumab | 2022 |
Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release.
Topics: Camptothecin; Cell Line, Tumor; Drug Liberation; Humans; Immunoconjugates; Stomach Neoplasms | 2023 |
Mechanistic biosynthesis of SN-38 coated reduced graphene oxide sheets for photothermal treatment and care of patients with gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Survival; Graphite; Humans; Infrared Rays; Microscopy, Fluorescence; Stomach Neoplasms | 2020 |
Breaking Barriers in HER2+ Cancers.
Topics: Camptothecin; Humans; Immunoconjugates; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2020 |
[The Efficacy of topo Ⅰ-pS10 Expression in Gastric Cancer as a Predictive Biomarker for Irinotecan Use].
Topics: Biomarkers; Camptothecin; DNA Topoisomerases, Type I; Humans; Irinotecan; Stomach Neoplasms | 2021 |
Efficacy of trastuzumab deruxtecan in an advanced gastric cancer patient with brain metastasis.
Topics: Aged; Antineoplastic Agents, Immunological; Brain Neoplasms; Camptothecin; Humans; Immunoconjugates; Male; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Treatment Outcome | 2021 |
Exposure-Response Relationships in Patients With HER2-Positive Metastatic Breast Cancer and Other Solid Tumors Treated With Trastuzumab Deruxtecan.
Topics: Adenocarcinoma; Antineoplastic Agents; Area Under Curve; Breast Neoplasms; Camptothecin; Clinical Trials as Topic; Humans; Immunoconjugates; Kaplan-Meier Estimate; Logistic Models; Multivariate Analysis; Proportional Hazards Models; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab | 2021 |
The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
Topics: Camptothecin; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL10; Chemokine CXCL11; Chemokine CXCL9; Chemotactic Factors; DNA Damage; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class I; Humans; Immunoconjugates; Receptor, ErbB-2; RNA, Messenger; Stomach Neoplasms; Trastuzumab; Up-Regulation | 2021 |
Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cost-Benefit Analysis; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2018 |
Gastrin induces multidrug resistance via the degradation of p27Kip1 in the gastric carcinoma cell line SGC7901.
Topics: Aged; Camptothecin; Carcinoma; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Gastrins; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Phosphorylation; Proteolysis; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Stomach Neoplasms | 2017 |
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Inbred BALB C; Mice, Nude; Multidrug Resistance-Associated Protein 2; Random Allocation; Receptor, ErbB-2; Stomach Neoplasms; Topoisomerase I Inhibitors; Trastuzumab | 2017 |
Irinotecan monotherapy as third-line or later treatment in advanced gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Female; Humans; Irinotecan; Japan; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Stomach Neoplasms | 2018 |
Synthesis and evaluation of asymmetric curcuminoid analogs as potential anticancer agents that downregulate NF-κB activation and enhance the sensitivity of gastric cancer cell lines to irinotecan chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Humans; Irinotecan; Molecular Structure; NF-kappa B; Stomach Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Drug Carriers; Drug Delivery Systems; Fluorouracil; Humans; Hyaluronic Acid; Irinotecan; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Stomach Neoplasms | 2017 |
5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorine; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Patient Safety; Platinum; Pyrimidines; Stomach Neoplasms; Taxoids; Treatment Outcome | 2018 |
Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Survival; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Humans; Injections, Intraperitoneal; Irinotecan; Mice, Nude; Neoplasm Proteins; Quercetin; Random Allocation; Specific Pathogen-Free Organisms; Stomach Neoplasms; Topoisomerase I Inhibitors; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Neuroendocrine Carcinoma of the Stomach: A Response to Combination Chemotherapy Consisting of Ramucirumab Plus Paclitaxel.
Topics: Aged; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Male; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2018 |
Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Female; Humans; Ki-67 Antigen; MAP Kinase Signaling System; Mice, Inbred NOD; Mice, SCID; Proto-Oncogene Proteins c-akt; Stomach Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2017 |
ZNF830 mediates cancer chemoresistance through promoting homologous-recombination repair.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Binding Sites; Camptothecin; Carrier Proteins; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA, Neoplasm; Drug Resistance, Neoplasm; Endodeoxyribonucleases; Epithelial Cells; Female; Genomic Instability; Humans; Hydroxyurea; Kruppel-Like Transcription Factors; Lung Neoplasms; Mice; Mice, Nude; Nuclear Proteins; Osteoblasts; Phosphorylation; Protein Binding; Recombinational DNA Repair; Stomach Neoplasms; Survival Analysis; Xenograft Model Antitumor Assays | 2018 |
[A Case of Locally Advanced Neuroendocrine Carcinoma of the Stomach Could be Curably Resected after Chemotherapy with CPT-11/CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms | 2017 |
[A Case of Successful CDDP plus CPT-11 Therapy for Recurrent Carcinomatous Lymphangiosis Occurring during Postoperative Adjuvant Therapy for Gastric Cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Gastrectomy; Humans; Irinotecan; Lymphangitis; Male; Recurrence; Stomach Neoplasms | 2017 |
[A Case of Advanced Gastric Cancer Treated with Curative Resection after Preoperative Secondary Chemotherapy with Irinotecan after Primary Chemotherapy with Docetaxel, Cisplatin, and S-1].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Gastrectomy; Humans; Irinotecan; Male; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2018 |
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cesarean Section; China; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Neoplasm Recurrence, Local; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pregnancy; Pregnancy Complications, Neoplastic; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate; Thiophenes | 2018 |
FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Case-Control Studies; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Synergism; Female; Fluorouracil; Gene Amplification; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Irinotecan; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Signal Transduction; Stomach Neoplasms; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult | 2013 |
Two-stage operation for synchronous triple primary cancer of the esophagus, stomach, and ampulla of Vater: report of a case.
Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Common Bile Duct Neoplasms; Diagnostic Imaging; Digestive System Surgical Procedures; Esophageal Neoplasms; Fatal Outcome; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasms, Multiple Primary; Plastic Surgery Procedures; Prostatic Neoplasms; Stomach Neoplasms | 2014 |
A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Biomarkers, Tumor; Camptothecin; Drug Screening Assays, Antitumor; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Methylation; Mice; Middle Aged; Models, Genetic; Neoplasm Proteins; Reproducibility of Results; Stomach Neoplasms; Sulfatases; Sulfotransferases; Xenograft Model Antitumor Assays | 2013 |
Risk factors for severe adverse effects and treatment-related deaths in Japanese patients treated with irinotecan-based chemotherapy: a postmarketing survey.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Asian People; Breast Neoplasms; Camptothecin; Colorectal Neoplasms; Death; Diarrhea; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Leukopenia; Logistic Models; Lung Neoplasms; Lymphoma; Male; Middle Aged; Neoplasms; Ovarian Neoplasms; Product Surveillance, Postmarketing; Risk Assessment; Risk Factors; Sex Factors; Skin Neoplasms; Stomach Neoplasms; Thrombocytopenia | 2013 |
Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Confidence Intervals; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Female; Fluorouracil; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Irinotecan; Male; Middle Aged; Neoplasm Proteins; Platinum; Quinazolines; RNA, Messenger; Stomach Neoplasms | 2013 |
A patient with scirrhous stomach cancer treated with combination of hyperthermotherapy and 5-aminolevulinic acid (ALA).
Topics: Adenocarcinoma, Scirrhous; Adult; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Dichloroacetic Acid; Docetaxel; Drug Combinations; Drug Therapy, Combination; Female; Humans; Hyperthermia, Induced; Irinotecan; Ovarian Neoplasms; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Photosensitizing Agents; Prognosis; Silicates; Stomach Neoplasms; Taxoids; Tegafur; Titanium | 2013 |
Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Asian People; Camptothecin; Esophageal Neoplasms; Female; Genotype; Glucuronosyltransferase; Humans; Irinotecan; Male; Middle Aged; Polymorphism, Genetic; Retrospective Studies; Stomach Neoplasms; Young Adult | 2013 |
Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Fluorouracil; Gastroscopy; Humans; Leucovorin; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Recurrence; Silicates; Stomach Neoplasms; Titanium; Tomography, X-Ray Computed | 2013 |
[Approximately four years of survival benefits for a case of gastric cancer postoperative carcinomatous peritonitis by combined modality therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms; Tegafur; Time Factors | 2013 |
[A case of synchronous liver metastasis originating from advanced gastric cancer treated with combination chemotherapy involving S-1 and surgical intervention].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2013 |
[A case of recurrence after resection of gastric cancer successfully treated by combination chemotherapy with CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stomach Neoplasms | 2013 |
Correlating preclinical animal studies and human clinical trials of a multifunctional, polymeric nanoparticle.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Cell Line, Tumor; Clinical Trials as Topic; Cyclodextrins; Dogs; Drug Delivery Systems; Female; Humans; Mice; Mice, Nude; Nanoconjugates; Rats; Stomach Neoplasms; Translational Research, Biomedical | 2013 |
Successful combination chemotherapy with irinotecan hydrochloride and cisplatin for primary gastric small cell carcinoma: report of a case.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Humans; Irinotecan; Male; Prognosis; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 2013 |
[Correlation between the methylation of SULF2 and WRN promoter and chemosensitivity to irinotecan in gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; DNA Methylation; Exodeoxyribonucleases; Humans; Irinotecan; Methylation; Promoter Regions, Genetic; RecQ Helicases; Stomach Neoplasms; Sulfatases; Sulfotransferases; Werner Syndrome Helicase | 2013 |
A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Etoposide; Female; Fluorouracil; Gemcitabine; Germany; Hospitals, University; Humans; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Prognosis; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Treatment Outcome | 2013 |
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Neoplasm Staging; Platinum; Prognosis; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2013 |
The association between chemosensitivity and Pgp, GST-π and Topo II expression in gastric cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cells, Cultured; Cisplatin; DNA Topoisomerases, Type II; Doxorubicin; Drug Resistance, Neoplasm; Fluorouracil; Gastric Mucosa; Glutathione S-Transferase pi; Humans; In Vitro Techniques; Mitomycin; Stomach; Stomach Neoplasms | 2013 |
FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Taxoids | 2013 |
Correlation between the methylation of SULF2 and WRN promoter and the irinotecan chemosensitivity in gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma; Carcinoma, Signet Ring Cell; DNA Methylation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Exodeoxyribonucleases; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Promoter Regions, Genetic; RecQ Helicases; Stomach Neoplasms; Sulfatases; Sulfotransferases; Werner Syndrome Helicase | 2013 |
Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Cisplatin; Cohort Studies; Colorectal Neoplasms; Combined Modality Therapy; Female; Humans; Hyperthermia, Induced; Irinotecan; Male; Mesothelioma; Middle Aged; Mitomycin; Neoplasms, Multiple Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Peritoneum; Prospective Studies; Pseudomyxoma Peritonei; Quality of Life; Stomach Neoplasms; Treatment Outcome | 2014 |
[A case of gastric carcinosarcoma treated with surgical resection and irinotecan and mitomycin C combination therapy].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinosarcoma; Combined Modality Therapy; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Metastasis; Stomach Neoplasms | 2014 |
[An effective treatment by chemotherapy with CDDP+CPT-11 for recurrent gastric cancer which S-1 cannot be used owing to adverse effects].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Contraindications; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2013 |
[A case of multiple distant lymph node metastases from advanced gastric cancer treated with adjuvant chemotherapy after total gastrectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplatin; Female; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Stomach Neoplasms | 2013 |
[Multidisciplinary therapy for 3 patients with lymph node recurrence after curative gastrectomy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Recurrence; Stomach Neoplasms | 2013 |
[A case of mixed adenoneuroendocrine carcinoma of the esophagogastric junction treated with neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Drug Combinations; Esophagogastric Junction; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Oxonic Acid; Stomach Neoplasms; Tegafur | 2013 |
[Cases of three patients undergoing chemotherapy for gastric cancer who developed Trousseau's syndrome].
Topics: Adult; Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Stroke; Tegafur | 2013 |
Not only chemotherapy in the second-line treatment of metastatic gastric cancer.
Topics: Camptothecin; Humans; Stomach Neoplasms; Taxoids | 2014 |
Marked antitumor effect of NK012, a SN-38-incorporating micelle formulation, in a newly developed mouse model of liver metastasis resulting from gastric cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Chemistry, Pharmaceutical; Drug Carriers; Female; Genes, Reporter; Humans; Irinotecan; Liver Neoplasms; Luciferases; Luminescent Measurements; Mice; Mice, SCID; Micelles; Stomach Neoplasms; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cisplatin; DNA Damage; DNA Repair; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Proteasome Endopeptidase Complex; RNA Interference; Signal Transduction; Stomach Neoplasms; Thioredoxins; Time Factors; Transfection; Ubiquitination; X-ray Repair Cross Complementing Protein 1 | 2014 |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Blood Transfusion; Camptothecin; Carcinoma; Colorectal Neoplasms; Combined Modality Therapy; Cytoreduction Surgical Procedures; Female; Gallbladder Neoplasms; Humans; Hyperthermia, Induced; Intraoperative Care; Irinotecan; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Peritoneal Neoplasms; Pseudomyxoma Peritonei; Stomach Neoplasms; Survival Rate; Tertiary Care Centers | 2014 |
[Chemotherapy and targeted therapy in liver metastasis from gastric cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Molecular Targeted Therapy; Stomach Neoplasms; Taxoids; Trastuzumab | 2014 |
[Trastuzumab combined with chemotherapy in patients with HER2-positive chemo-refractory advanced gastric or gastro-esophageal junction adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Esophagogastric Junction; Fatigue; Female; Follow-Up Studies; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neutropenia; Paclitaxel; Pyrimidines; Receptor, ErbB-2; Remission Induction; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab | 2014 |
Antitumor effects of a sirtuin inhibitor, tenovin-6, against gastric cancer cells via death receptor 5 up-regulation.
Topics: Activating Transcription Factor 6; Antineoplastic Agents; Apoptosis; Benzamides; Camptothecin; Cell Line; Cell Line, Tumor; Docetaxel; eIF-2 Kinase; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Irinotecan; MCF-7 Cells; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Sirtuin 1; Stomach Neoplasms; Taxoids; Transcription Factor CHOP; Tumor Suppressor Protein p53; Up-Regulation | 2014 |
Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and ci
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Febrile Neutropenia; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2014 |
[Clinical efficacy of low-dose CDDP and CPT-11 therapy as second- or third-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Recurrence; Retrospective Studies; Stomach Neoplasms | 2014 |
An on-chip small intestine-liver model for pharmacokinetic studies.
Topics: Animals; Caco-2 Cells; Camptothecin; Computer Simulation; Cyclophosphamide; Drug Screening Assays, Antitumor; Epirubicin; Hep G2 Cells; Humans; Intestine, Small; Irinotecan; Lab-On-A-Chip Devices; Liver; Liver Neoplasms; Lung; Lung Neoplasms; Organ Culture Techniques; Stomach Neoplasms | 2015 |
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Camptothecin; Capecitabine; Carboplatin; Deoxycytidine; Esophageal Neoplasms; Esophagogastric Junction; Fluorouracil; Humans; Irinotecan; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Trastuzumab | 2014 |
[A case of advanced gastric cancer successfully treated with second-line chemotherapy followed by curative conversion gastrectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Peritoneal Neoplasms; Remission Induction; Stomach Neoplasms; Tegafur | 2014 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Mice; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays | 2015 |
Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Apoptosis; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Clinical Trials as Topic; Female; Gene Expression Regulation, Neoplastic; Humans; Immunoconjugates; Irinotecan; Mice; Pancreatic Neoplasms; Signal Transduction; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Case-Control Studies; Cyclooxygenase 2; DNA Topoisomerases, Type II; DNA-Binding Proteins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epirubicin; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Immunohistochemistry; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Tumor Cells, Cultured; Vincristine | 2015 |
[Long-term survival and effective treatment of synchronous liver metastases in a case of primary gastric choriocarcinoma by using hepatic arterial infusion chemotherapy, irinotecan, and cisplatin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Choriocarcinoma; Cisplatin; Fatal Outcome; Gastrectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms | 2015 |
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Proportional Hazards Models; Prospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2015 |
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2-SN-38 Antibody Conjugate (Sacituzumab Govitecan).
Topics: Animals; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Humans; Immunoconjugates; Irinotecan; Mice; Pancreatic Neoplasms; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2015 |
[Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer].
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Stomach Neoplasms; Treatment Outcome | 2015 |
[Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Organoplatinum Compounds; Stomach Neoplasms | 2015 |
Arsenic sulfide combined with JQ1, chemotherapy agents, or celecoxib inhibit gastric and colon cancer cell growth.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenicals; Azepines; Camptothecin; Celecoxib; Cell Line, Tumor; Cisplatin; Colonic Neoplasms; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; p38 Mitogen-Activated Protein Kinases; Stomach Neoplasms; Sulfides; Triazoles; Tumor Suppressor Protein p53 | 2015 |
Possibility of Müller Cell Dysfunction as the Pathogenesis of Paclitaxel Maculopathy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Substitution; Electroretinography; Ependymoglial Cells; Fluorescein Angiography; Humans; Irinotecan; Macular Edema; Male; Paclitaxel; Stomach Neoplasms; Tomography, Optical Coherence | 2016 |
Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Epirubicin; Female; Fluorouracil; France; Humans; Irinotecan; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Middle Aged; Multivariate Analysis; Ovarian Neoplasms; Ovariectomy; Prognosis; Proportional Hazards Models; Retrospective Studies; Stomach Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2016 |
[Pre-Operative Treatment with Transcatheter Arterial Chemoembolization (TACE) and Hepatic Arterial Infusion (HAI) for Liver Metastasis from Gastric Cancer--A Case Report].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Combined Modality Therapy; Fluorouracil; Gastrectomy; Hepatectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Stomach Neoplasms | 2015 |
[A Case of Successful Treatment of Metachronous Liver Metastasis from Gastric Cancer with Hepatectomy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastrectomy; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2015 |
[A Case of Advanced Gastric Cancer with Long-Term Survival after Chemotherapy with Combined S-1 and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Prognosis; Splenectomy; Stomach Neoplasms; Tegafur; Time Factors | 2015 |
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
Topics: Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Camptothecin; Carbonic Anhydrase IX; Cell Line, Tumor; Cyclodextrins; DNA Topoisomerases, Type I; Endoscopy; Esophageal Neoplasms; Humans; Mice; Nanoparticles; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Usefulness of diagnostic laparoscopy with 5-aminolevulinic acid (ALA)-mediated photodynamic diagnosis for the detection of peritoneal micrometastasis in advanced gastric cancer after chemotherapy.
Topics: Adult; Aged; Aminolevulinic Acid; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Diagnostic Imaging; Female; Fluorouracil; Humans; Irinotecan; Laparoscopy; Male; Middle Aged; Peritoneal Neoplasms; Photosensitizing Agents; Stomach Neoplasms | 2016 |
Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity.
Topics: Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Bystander Effect; Camptothecin; Cell Line, Tumor; Cell Membrane Permeability; Cell Proliferation; Female; Humans; Immunoconjugates; Maytansine; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Receptor, ErbB-2; Stomach Neoplasms; Topoisomerase I Inhibitors; Trastuzumab | 2016 |
Dual-targeting hybrid nanoparticles for the delivery of SN38 to Her2 and CD44 overexpressed human gastric cancer.
Topics: Animals; Camptothecin; Cell Line, Tumor; Drug Delivery Systems; Humans; Hyaluronan Receptors; Hyaluronic Acid; Irinotecan; Mice; Mice, Nude; Nanoparticles; Receptor, ErbB-2; Stomach Neoplasms; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Combining ABCG2 Inhibitors with IMMU-132, an Anti-Trop-2 Antibody Conjugate of SN-38, Overcomes Resistance to SN-38 in Breast and Gastric Cancers.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gene Expression; Humans; Immunoconjugates; Inhibitory Concentration 50; Irinotecan; Mice; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Efficacy and safety of irinotecan monotherapy as third-line treatment for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2016 |
ATM Expression Predicts Veliparib and Irinotecan Sensitivity in Gastric Cancer by Mediating P53-Independent Regulation of Cell Cycle and Apoptosis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Ataxia Telangiectasia Mutated Proteins; Benzimidazoles; Camptothecin; Cell Cycle; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Histones; Humans; Inhibitory Concentration 50; Irinotecan; Oncogene Protein p21(ras); Phosphorylation; Proto-Oncogene Proteins; Stomach Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Camptothecin; Diarrhea; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Prospective Studies; Response Evaluation Criteria in Solid Tumors; Retreatment; Stomach Neoplasms; Survival Rate; Vomiting; White People | 2016 |
[Second-line treatment for metastatic or locally advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Humans; Irinotecan; Molecular Targeted Therapy; Paclitaxel; Ramucirumab; Salvage Therapy; Stomach Neoplasms; Taxoids | 2016 |
Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes.
Topics: Adult; Aged; Antineoplastic Agents; Camptothecin; Capecitabine; Disease-Free Survival; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Oxonic Acid; Platinum Compounds; Proportional Hazards Models; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur; Treatment Outcome | 2017 |
[Curative Resection for Chemorefractory Advanced Gastric Cancer with Pancreatic Invasion by Pancreatoduodenectomy - A Case Report].
Topics: Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Combinations; Female; Humans; Irinotecan; Neoplasm Invasiveness; Oxonic Acid; Pancreas; Pancreaticoduodenectomy; Stomach Neoplasms; Tegafur; Treatment Outcome | 2016 |
[A Case of Multiple Liver Metastasis from Gastric Cancer Successfully Treated with CPT-11 as Third-Line Chemotherapy].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Fatal Outcome; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms; Time Factors | 2016 |
[A Case of Recurrent Gastric Cancer with Recurrent Celiac Lymph Node Metastasis Successfully Treated with Chemoradiotherapy and CPT-11 plus CDDP Therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradiotherapy; Cisplatin; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Stomach Neoplasms; Treatment Outcome | 2016 |
Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Down-Regulation; Epoxy Compounds; Gene Expression Regulation, Neoplastic; HSP70 Heat-Shock Proteins; Humans; Irinotecan; Mice, Nude; Organophosphates; Phenanthrenes; Prodrugs; Reverse Transcriptase Polymerase Chain Reaction; Sp1 Transcription Factor; Stomach Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Glucuronosyltransferase; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Nausea; Neoplasm Metastasis; Stomach Neoplasms; Treatment Outcome; Vomiting | 2017 |
Effects of 5-fluorouracil, adriamycin and irinotecan on HSC-39, a human scirrhous gastric cancer cell line.
Topics: Adenocarcinoma, Scirrhous; Apoptosis; Camptothecin; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Necrosis; Reactive Oxygen Species; Stomach Neoplasms | 2017 |
Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Combinations; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Meta-Analysis as Topic; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Randomized Controlled Trials as Topic; Stomach Neoplasms; Taxoids; Tegafur | 2008 |
[Long survival of advanced gastric cancer patient after total gastrectomy and postoperative treatment with S-1 despite S-1+CDDP+CPT-11 causing perforation].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Irinotecan; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[A case of Stage IV gastric cancer with liver and peritoneal metastases responding completely to tailored S-1/CPT- 11 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Liver Neoplasms; Male; Neoplasm Staging; Oxonic Acid; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
[Efficacy of low-dose CDDP and CPT-11 for patients with intestinal type of gastric adenocarcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Gastroscopy; Humans; Intestinal Neoplasms; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[A case of advanced gastric cancer with pulmonary carcinomatous lymphangitis and paraaortic lymph node metastases responding to combination chemotherapy of S-1 and irinotecan(CPT-11)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Drug Combinations; Female; Gastroscopy; Humans; Irinotecan; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Failure | 2008 |
[Three cases with liver metastasis from gastric or colon cancer successfully treated with S-1 combined with CPT- 11].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Drug Combinations; Female; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
Irinotecan plus cisplatin therapy and S-1 plus cisplatin therapy for advanced or recurrent gastric cancer in a single institution.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retreatment; Stomach Neoplasms; Survival Analysis; Tegafur; Treatment Outcome; Young Adult | 2008 |
Antitumor effect of SN-38-releasing polymeric micelles, NK012, on spontaneous peritoneal metastases from orthotopic gastric cancer in mice compared with irinotecan.
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Micelles; Microscopy, Fluorescence; Peritoneal Neoplasms; Stomach Neoplasms; Tissue Distribution | 2008 |
[A case of recurrent gastroesophageal junction adenocarcinoma successfully treated with radiation plus chemotherapy (5-FU+CDDP, S-1, Paclitaxel, CPT-11) for long-term survival with good QOL].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Esophageal Neoplasms; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2008 |
[Marked response to combination chemotherapy using S-1, CPT-11 for lymph node metastasis of gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Drug Combinations; Humans; Irinotecan; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2008 |
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quality of Life; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
[A case of unresectable advanced gastric cancer successfully treated with continuous S-1 + CPT-11 chemotherapy accompanied by dose reduction against grade 4 hematological adverse event].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Blood Cell Count; Camptothecin; Cell Proliferation; Drug Combinations; Gastroscopy; Humans; Irinotecan; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2008 |
[Advanced gastric cancer showing complete response to neoadjuvant chemotherapy with CPT-11 and S-1-a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[A case of simultaneous double cancers with multiple liver metastases responding to S-1+CPT-11].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoembryonic Antigen; Drug Combinations; Endoscopy, Gastrointestinal; Humans; Irinotecan; Liver Neoplasms; Male; Neoplasms, Multiple Primary; Oxonic Acid; Rectal Neoplasms; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
[A case of recurrence after curative total gastrectomy for gastric cancer successfully treated by combination chemotherapy with CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Neoplasm Staging; Positron-Emission Tomography; Recurrence; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 2009 |
Need for a new treatment strategy: leptomeningeal carcinomatosis from gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Meningeal Carcinomatosis; Middle Aged; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2009 |
Activity of S-1 in advanced or recurrent gastric cancer patients after failure of prior chemotherapy, including irinotecan + cisplatin or fluorouracil (except S-1).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur | 2009 |
A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Multivariate Analysis; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome; Young Adult | 2009 |
[Risk associated with severe hematological toxicity in patients with advanced or recurrent gastric cancer receiving primary combination chemotherapy of cisplatin and S-1 or cisplatin and irinotecan hydrochloride].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Camptothecin; Cisplatin; Drug Combinations; Hematopoiesis; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Risk Factors; Stomach Neoplasms; Tegafur | 2009 |
Treatment of gastric cancer cells with 5-fluorouracil/leucovorin and irinotecan induces distinct alterations in the mRNA expression of the apoptosis-related genes, including the novel gene BCL2L12.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Camptothecin; Cell Line, Tumor; Drug Therapy, Combination; Fluorouracil; Gene Expression; Humans; Irinotecan; Leucovorin; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Stomach Neoplasms | 2009 |
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; Chromatography, Liquid; Colonic Neoplasms; Colony-Forming Units Assay; Drug Synergism; ErbB Receptors; Flow Cytometry; Humans; Irinotecan; Lapatinib; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
[A case of marked response to CPT-11+CDDP neoadjuvant chemotherapy for advanced gastric cancer with paraaortic lymph node metastasis enabling curative resection and over 10-year survival].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Cisplatin; Combined Modality Therapy; Female; Humans; Irinotecan; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms | 2009 |
Predictive factors for the efficacy of cetuximab plus chemotherapy as salvage therapy in metastatic gastric cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; DNA Mutational Analysis; Exanthema; Female; Humans; Irinotecan; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Metastasis; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Female; Fever; Fluorouracil; Follow-Up Studies; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neutropenia; Retrospective Studies; Stomach Neoplasms; Taxoids; Young Adult | 2010 |
[Report of a case successfully treated with chemo-radiation against local recurrence after gastric cancer surgery].
Topics: Aged; Ambulatory Care; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Paclitaxel; Splenectomy; Stomach Neoplasms; Tegafur | 2009 |
Expression levels of insulin-like growth factor-1 and multidrug resistance-associated protein-1 indicate poor prognosis in patients with gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Immunohistochemistry; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Prognosis; Receptor, IGF Type 1; Stomach Neoplasms; Survival Rate | 2009 |
Irinotecan plus capecitabine as a second-line treatment after failure of 5-fluorouracil and platinum in patients with advanced gastric cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Stomach Neoplasms | 2009 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival by successive treatments with S-1 in combination with CDDP, paclitaxel and irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Radiography; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[A case of recurrent gastric cancer during adjuvant chemotherapy with S-1, treated by S-1 combination chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Fatal Outcome; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Recurrence; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2009 |
Treatment of gastric cancer in Asia: the missing link.
Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Japan; Oxonic Acid; Patient Selection; Risk Assessment; Stomach Neoplasms; Tegafur; Time Factors; Treatment Outcome | 2009 |
[Combination chemotherapy of S-1 and CPT-11 for advanced recurrent gastric cancer].
Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2009 |
[A case of advanced gastric cancer that a medical therapy effect was provided grade 3 by a histopathological diagnosis after long-term chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2009 |
[A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Metastasis; Stomach Neoplasms; Tegafur; Uracil | 2009 |
[A long term survivor of advanced gastric cancer treated with multi-drug combination chemotherapy].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Floxuridine; Humans; Irinotecan; Male; Paclitaxel; Stomach Neoplasms | 2009 |
[A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2009 |
[A case of bilateral pulmonary metastasis from gastric cancer performed radical thoracoscopic lobectomy after neoadjuvant chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Oxonic Acid; Pneumonectomy; Stomach Neoplasms; Tegafur; Thoracoscopy | 2009 |
Weekly paclitaxel for heavily treated advanced or recurrent gastric cancer refractory to fluorouracil, irinotecan, and cisplatin.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Recurrence; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome; Young Adult | 2009 |
[Retrospective analysis of generalized chemotherapy for unresectable advanced gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Retrospective Studies; Stomach Neoplasms; Survival Rate; Tegafur | 2010 |
[A case of advanced gastric cancer with a complete response to S-1 plus CPT-11 chemotherapy for eight years].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Male; Oxonic Acid; Pyloric Antrum; Remission Induction; Stomach Neoplasms; Tegafur | 2010 |
[Successful treatment with S-1 + CPT-11 for hepatic metastasis from gastric cancer--a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[A case of S-1-resistant gastric cancer with multiple bone metastases and disseminated intravascular coagulation--effective treatment by combined chemotherapy with CDDP and CPT-11].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Disseminated Intravascular Coagulation; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[S-1 + CPT-11 combination therapy with continuing 30-month CR in a recurrent gastric cancer with para-aortic lymph node metastasis in adjuvant chemotherapy with S-1--a case report].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Chemotherapy, Adjuvant; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Splenectomy; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Recurrence, Local; Organoplatinum Compounds; Recurrence; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 2010 |
Usefulness of staging laparoscopy for advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Retrospective Studies; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2010 |
[A case of early poorly-differentiated neuroendocrine carcinoma of stomach].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cell Differentiation; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2010 |
Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stomach Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Establishment and characterization of multidrug-resistant gastric cancer cell lines.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B; Calcium-Calmodulin-Dependent Protein Kinases; Camptothecin; Cell Cycle; Cell Line, Tumor; Death-Associated Protein Kinases; Deoxycytidine; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms | 2010 |
[A case of gastric large cell neuroendocrine carcinoma (LCNEC) for whom chemotherapy of CDDP+CPT-11 proved very effective].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Cisplatin; Gastroscopy; Humans; Irinotecan; Male; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.
Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Fluorouracil; Gastrectomy; Humans; Leucovorin; Liver Neoplasms; Male; Neoplasm Staging; Neoplasms, Second Primary; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2011 |
[Third-line CPT-11 chemotherapy for gastric cancer cases of non-curative gastrectomy or recurrence].
Topics: Aged; Antineoplastic Agents; Camptothecin; Female; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Recurrence; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2010 |
[A resected case of effective treatment with S-1+CPT-11 combination chemotherapy for advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Gastrectomy; Gastroscopy; Humans; Irinotecan; Male; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2010 |
[A case of gastric adenosquamous carcinoma successfully treated with second-line chemotherapy (CPT-11 and CDDP)].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Cisplatin; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Neoadjuvant Therapy; Positron-Emission Tomography; Remission Induction; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
Second-line chemotherapy with irinotecan plus cisplatin after the failure of S-1 monotherapy for advanced gastric cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Confidence Intervals; Disease Progression; Drug Combinations; Female; Health Status Indicators; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Oxonic Acid; Retrospective Studies; Stomach Neoplasms; Tegafur; Time Factors; Treatment Failure | 2010 |
Population pharmacokinetics of CPT-11 (irinotecan) in gastric cancer patients with peritoneal seeding after its intraperitoneal administration.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cohort Studies; Female; Humans; Infusions, Parenteral; Irinotecan; Male; Models, Theoretical; Neoplasm Seeding; Stomach Neoplasms | 2010 |
Effects of genetic polymorphisms in the ABCB1 gene on clinical outcomes in patients with gastric cancer treated by second-line chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cisplatin; Cohort Studies; Docetaxel; Female; Fluorouracil; Follow-Up Studies; Genotype; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Polymerase Chain Reaction; Polymorphism, Genetic; Prognosis; Retrospective Studies; Risk Factors; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids | 2010 |
[Effects of irinotecan and 5-FU combination therapy in gastric cancer--is combination therapy synergic?].
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Antagonism; Drug Synergism; Female; Fluorouracil; Humans; In Vitro Techniques; Irinotecan; Male; Middle Aged; Stomach Neoplasms | 2010 |
[A case of pneumocystis pneumonia during chemotherapy for gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Dexamethasone; Drug Combinations; Fatal Outcome; Glucocorticoids; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pneumonia, Pneumocystis; Stomach Neoplasms; Tegafur; Trimethoprim, Sulfamethoxazole Drug Combination | 2010 |
[A clinical case of lymph node recurrence after resection of gastric cancer successfully treated by combination chemotherapy with irinotecan and cisplatin].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[A case of unresectable and multiple advanced primary cancers of the stomach and rectosigmoid colon with hepatic metastases successfully treated with FOLFIRI for local control of a gastric lesion].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Sigmoid Neoplasms; Stomach Neoplasms | 2010 |
[A successful case with CPT-11 + CDDP chemotherapy for recurrent gastric cancer of the remnant stomach].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Gastrectomy; Gastric Stump; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Stomach Neoplasms | 2010 |
[A long-term survival case of bilateral ovarian metastasis of progressive gastric cancer treated by chemotherapy].
Topics: Adenocarcinoma, Scirrhous; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Docetaxel; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Ovarian Neoplasms; Ovariectomy; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
[Two cases of gastric endocrine cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Endocrine Gland Neoplasms; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2010 |
[A case of gastric endocrine cell carcinoma with liver metastases treated with S-1/CDDP].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Endocrine Gland Neoplasms; Gastrectomy; Hepatectomy; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Oxonic Acid; Stomach Neoplasms; Tegafur; Treatment Outcome | 2010 |
[A case of synchronous double cancer of stomach and lung responding to neoadjuvant chemotherapy].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Humans; Irinotecan; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasms, Multiple Primary; Oxonic Acid; Stomach Neoplasms; Taxoids; Tegafur | 2010 |
Docetaxel and irinotecan as second-line therapy for advanced oesophagogastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies; Disease Progression; Docetaxel; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Prognosis; Retrospective Studies; Stomach Neoplasms; Taxoids; Treatment Outcome | 2011 |
Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cetuximab; Cyclin-Dependent Kinase Inhibitor p16; Down-Regulation; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Signal Transduction; Stomach Neoplasms; Tumor Suppressor Protein p53; Up-Regulation | 2011 |
Genome-wide analysis of microRNA and mRNA expression signatures in hydroxycamptothecin-resistant gastric cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; MicroRNAs; RNA, Messenger; Stomach Neoplasms | 2011 |
Neuroendocrine tumors of the stomach: chemotherapy with cisplatin plus irinotecan is effective for gastric poorly-differentiated neuroendocrine carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Neuroendocrine; Cisplatin; Disease-Free Survival; Female; History, 17th Century; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Retrospective Studies; Stomach Neoplasms | 2011 |
Survival and prognosticators of gastric cancer that recurs after adjuvant chemotherapy with S-1.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Palliative Care; Proportional Hazards Models; Stomach Neoplasms; Taxoids; Tegafur | 2011 |
Association of fluoropyrimidines, platinum agents, taxanes, and irinotecan in any line of chemotherapy with survival in patients with advanced gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Cohort Studies; Female; Fluorouracil; Humans; Irinotecan; Kaplan-Meier Estimate; Male; Middle Aged; Platinum Compounds; Retrospective Studies; Stomach Neoplasms; Taxoids | 2011 |
Improvement of oral intake following chemotherapy in gastric cancer patients with an inability to eat.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feeding and Eating Disorders; Female; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Peritoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Irinotecan is inactive as a first-line treatment, but plays an important part in gastric cancer treatment.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Stomach Neoplasms | 2011 |
Anti-stromal therapy with imatinib inhibits growth and metastasis of gastric carcinoma in an orthotopic nude mouse model.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Camptothecin; Cell Proliferation; Fluorescent Antibody Technique; Humans; Imatinib Mesylate; Immunohistochemistry; In Situ Nick-End Labeling; Irinotecan; Male; Mice; Mice, Nude; Microscopy, Confocal; Neoplasm Metastasis; Neovascularization, Pathologic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2011 |
[Palliative anti-cancer chemotherapy is safely executable in a hemodialytic patient with unresectable advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Humans; Irinotecan; Kidney Failure, Chronic; Male; Neoplasm Staging; Palliative Care; Renal Dialysis; Stomach Neoplasms; Taxoids; Tegafur; Tomography, X-Ray Computed | 2011 |
Biweekly cetuximab and irinotecan as second-line therapy in patients with gastro-esophageal cancer previously treated with platinum.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Esophageal Neoplasms; Female; Follow-Up Studies; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Salvage Therapy; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2011 |
A FGFR2 inhibitor, Ki23057, enhances the chemosensitivity of drug-resistant gastric cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Proliferation; Deoxycytidine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Endonucleases; Etoposide; Gemcitabine; Humans; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinolines; Receptor, Fibroblast Growth Factor, Type 2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Palliative Care; Prognosis; Radionuclide Imaging; Stomach Neoplasms; Treatment Outcome | 2011 |
[A resected case of advanced gastric cancer with multiple liver metastasis successfully treated by preoperative and postoperative S-1/CPT-11 combination chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Combined Modality Therapy; Drug Combinations; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2011 |
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Retrospective Studies; Stomach Neoplasms | 2011 |
Early gastric cancer combined with multiple metachronous osteosclerotic bone and bone marrow metastases that responded to chemoradiotherapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Bone Neoplasms; Camptothecin; Chemoradiotherapy; Drug Combinations; Female; Humans; Lymphatic Metastasis; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur; Treatment Outcome | 2011 |
[Clinical efficacy and safety of CPT-11+CDDP therapy as third-line chemotherapy for advanced and recurrent gastric cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Recurrence; Salvage Therapy; Stomach Neoplasms; Survival Rate | 2011 |
[A case of advanced gastric cancer with multiple liver metastasis responding to S-1 and irinotecan combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Fatal Outcome; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Stomach Neoplasms; Tegafur | 2011 |
[Irinotecan as second-line chemotherapy for 5-FU-resistant gastric cancer with disseminated intravascular coagulation: a case report].
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Disseminated Intravascular Coagulation; Fatal Outcome; Female; Fluorouracil; Humans; Irinotecan; Middle Aged; Neoplasm Staging; Salvage Therapy; Stomach Neoplasms | 2011 |
Irinotecan as the key chemotherapeutic agent in second-line treatment of metastatic gastric cancer after failure of first-line S-1 or S-1/CDDP therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Neoplasm Metastasis; Oxonic Acid; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Tegafur | 2011 |
ERas enhances resistance to CPT-11 in gastric cancer.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Embryonic Stem Cells; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Irinotecan; Models, Biological; NF-kappa B; Protein Binding; ras Proteins; Sirolimus; Stomach Neoplasms; Up-Regulation | 2011 |
Successful treatment of a patient with HER2-positive metastatic gastric cancer with third-line combination therapy with irinotecan, 5-fluorouracil, leucovorin and trastuzumab (FOLFIRI-T).
Topics: Abdominal Neoplasms; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Fluorouracil; Gastrectomy; Gene Expression Regulation, Neoplastic; Humans; Leucovorin; Lymph Node Excision; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Receptor, ErbB-2; Reoperation; Stomach Neoplasms; Tomography, X-Ray Computed; Trastuzumab; Ultrasonography | 2011 |
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Irinotecan; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Stomach Neoplasms | 2011 |
In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Docetaxel; ErbB Receptors; Genes, ras; Humans; Irinotecan; Male; Mice; Mice, Nude; Mutation; Proto-Oncogene Proteins B-raf; Stomach Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer.
Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cyclodextrins; Drug Carriers; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Nanoparticles; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2012 |
[Comparison of the toxicities and efficacies of the combination chemotherapy regimens in advanced gastric cancer patients who achieved complete response after chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leucovorin; Leukopenia; Male; Middle Aged; Mucositis; Nausea; Neoplasm Staging; Organoplatinum Compounds; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Tomography, X-Ray Computed; Vomiting | 2011 |
[A case of advanced gastric cancer with splenic vein thrombus successfully treated with S-1 plus CPT-11 neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Oxonic Acid; Remission Induction; Splenic Vein; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed; Venous Thrombosis | 2011 |
Trastuzumab has opposing effects on SN-38-induced double-strand breaks and cytotoxicity in HER2-positive gastric cancer cells depending on administration sequence.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Camptothecin; Cell Cycle; Cell Proliferation; DNA Breaks, Double-Stranded; Drug Administration Schedule; Flow Cytometry; Humans; Irinotecan; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptor, ErbB-2; Stomach Neoplasms; Trastuzumab; Tumor Cells, Cultured | 2012 |
[A case of S-1-resistant resected advanced gastric cancer with para-aortic lymph node recurrence responding to bi-weekly CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Cisplatin; Drug Combinations; Drug Resistance, Neoplasm; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Oxonic Acid; Recurrence; Stomach Neoplasms; Tegafur | 2012 |
[Successful management of liver metastasis from gastric adenosquamous carcinoma with adjuvant chemotherapy and radiofrequency ablation].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Adenosquamous; Catheter Ablation; Cisplatin; Combined Modality Therapy; Humans; Irinotecan; Liver Neoplasms; Male; Stomach Neoplasms | 2012 |
Gastrointestinal cancer: Salvage chemotherapy in gastric cancer--more than a straw?
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Docetaxel; Drug Resistance, Neoplasm; Humans; Irinotecan; Prognosis; Salvage Therapy; Stomach Neoplasms; Taxoids | 2012 |
[A case of an advanced gastric cancer patient on hemodialysis achieving long-term progression-free survival after CPT-11+CDDP therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Disease-Free Survival; Fatal Outcome; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Renal Dialysis; Stomach Neoplasms; Time Factors | 2012 |
Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Retreatment; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Taxoids; Young Adult | 2012 |
Significant prognostic factors in patients with Stage IV gastric cancer with special reference to the curability of surgery.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Gastrectomy; Humans; Irinotecan; Kaplan-Meier Estimate; Multivariate Analysis; Neoplasm Staging; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2013 |
[A case of gastric cancer with peritoneal dissemination who achieved long survival from control of ascites for over 2 years by successive treatments with S-1 in combination with docetaxel as first-line followed by irinotecan in combination with cisplatin
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Camptothecin; Cisplatin; Docetaxel; Drug Combinations; Fatal Outcome; Humans; Irinotecan; Male; Oxonic Acid; Peritoneal Neoplasms; Salvage Therapy; Stomach Neoplasms; Taxoids; Tegafur | 2012 |
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease-Free Survival; Docetaxel; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Retrospective Studies; Stomach Neoplasms; Survival Rate; Taxoids; Turkey | 2012 |
[A patient with gastric small cell carcinoma who died from meningitis carcinomatosa after CDDP+CPT-11 chemotherapy with good response].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Fatal Outcome; Humans; Male; Meningeal Carcinomatosis; Middle Aged; Stomach Neoplasms | 2012 |
The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neoplasm; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Grading; Neutropenia; Platinum Compounds; Remission Induction; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis; Taxoids; Young Adult | 2012 |
Chemosensitivity in ovarian metastases from gastric cancer: a case series.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms | 2013 |
Double pancreatic and gastric adenocarcinomas: a rare association.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Neoplasms, Multiple Primary; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Rare Diseases; Stomach Neoplasms; Tomography, X-Ray Computed | 2013 |
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Carcinoma, Signet Ring Cell; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Platinum; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2013 |
[A case of recurrent gastric cancer responding to CPT-11].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Stomach Neoplasms | 2012 |
[A case of recurrent gastric cancer successfully treated by a combination of CPT-11 and CDDP as the third-line chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Humans; Irinotecan; Lymphatic Metastasis; Male; Recurrence; Salvage Therapy; Stomach Neoplasms | 2012 |
[Chemotherapy-mediated tumor regression in a patient with stage IV stomach small cell cancer].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur | 2012 |
[A case of gastric endocrine cell carcinoma that responded to chemotherapy with CPT-11+CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Endocrine Gland Neoplasms; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms | 2012 |
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Humans; Irinotecan; Isoenzymes; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Pharmacogenetics; Polymorphism, Genetic; Stomach Neoplasms | 2013 |
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Relationship, Drug; Etoposide; Fluorouracil; Gene Expression Regulation, Enzymologic; Humans; Irinotecan; Leucovorin; Paclitaxel; Real-Time Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms | 2013 |
Oncolysis of human gastric cancers by an E1B 55 kDa-deleted YKL-1 adenovirus.
Topics: Adenocarcinoma; Adenovirus E1B Proteins; Adenoviruses, Human; Binding Sites; Camptothecin; Cytopathogenic Effect, Viral; DNA, Recombinant; DNA, Viral; Gene Deletion; Genes, p53; Genetic Vectors; Humans; Mutation, Missense; Neoplasm Proteins; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Protein Binding; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Virus Replication | 2002 |
[Three patients with advanced nonresectable and recurrent gastric cancer responding to chronomodulation chemotherapy with tegafur + cisplatin + isovorin followed by CPT-11 administration].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy; Cisplatin; Female; Humans; Irinotecan; Leucovorin; Male; Middle Aged; Stomach Neoplasms; Tegafur | 2002 |
Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers - a new active regimen.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cisplatin; Disease Progression; Esophageal Neoplasms; Female; Gastrointestinal Diseases; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Mitomycin; Neutropenia; Pancreatic Neoplasms; Stomach Neoplasms; Treatment Outcome | 2002 |
Induction of hRAD9 is required for G2/M checkpoint signal transduction in gastric cancer cells.
Topics: Adenocarcinoma; Apoptosis; Camptothecin; Cell Cycle Proteins; DNA Damage; DNA Fragmentation; DNA, Neoplasm; Flow Cytometry; G2 Phase; Gene Expression Regulation, Neoplastic; Genes, p53; Humans; Mitosis; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured; Ultraviolet Rays | 2002 |
[A case of postoperative liver metastasis of alpha-fetoprotein producing gastric cancer successfully treated with intrahepatic chemotherapy (adriamycin, cisplatin, irinotecan hydrochloride)].
Topics: alpha-Fetoproteins; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Gastrectomy; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms | 2002 |
[Pharmacokinetic study of CPT-11, SN-38 and SN-38 glucuronide in the ascites, plasma and bile after intraperitoneal administration of CPT-11].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Ascites; Bile; Camptothecin; Glucuronides; Humans; Infusions, Parenteral; Irinotecan; Male; Stomach Neoplasms | 2002 |
[A case of gastric cancer associated with synchronous liver metastasis successfully treated with combination therapy of systemic and hepatic arterial infusion chemotherapy].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Methotrexate; Middle Aged; Stomach Neoplasms | 2002 |
MAPK signaling is involved in camptothecin-induced cell death.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Camptothecin; Caspase 3; Caspase 8; Caspase 9; Caspase Inhibitors; Caspases; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Cysteine Endopeptidases; Enzyme Activation; Enzyme Inhibitors; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured | 2002 |
[Effectiveness of chemotherapy for outpatients with gastric or colorectal cancer].
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Middle Aged; Outpatients; Oxonic Acid; Paclitaxel; Pyridines; Retrospective Studies; Stomach Neoplasms; Tegafur | 2002 |
Irinotecan plus low-dose cisplatin for alpha-fetoprotein-producing gastric carcinoma with multiple liver metastases: report of two cases.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Male; Middle Aged; Stomach Neoplasms; Tomography, X-Ray Computed | 2002 |
Pharmacokinetic study of two infusion schedules of irinotecan combined with cisplatin in patients with advanced gastric cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Infusions, Intravenous; Irinotecan; Male; Middle Aged; Neoplasm Staging; Stomach Neoplasms; Time Factors; Topoisomerase I Inhibitors | 2003 |
Activity and safety of a low dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin for relapsed gastric cancer patients: a preliminary report.
Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Diarrhea; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Irinotecan; Japan; Male; Middle Aged; Neoplasm Recurrence, Local; Stomach Neoplasms; Survival Analysis; Time Factors; Treatment Outcome | 2003 |
[The evaluation of LFH or LFPH in the treatment of advanced cancer of gastric cardia and colorectal cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Stomach Neoplasms | 2003 |
[A case of gastric cancer with multiple liver metastasis responding to combination therapy of CPT-11 and CDDP].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms | 2003 |
[A patient with peritoneal metastasis from gastric cancer who responded to weekly chemotherapy with paclitaxel on the third line and could take meal].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Peritoneal Neoplasms; Silicates; Stomach Neoplasms; Titanium | 2003 |
[A case of effective weekly paclitaxel administration for metastatic gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2003 |
CPT-11 and cisplatin in the treatment of advanced gastric cancer in Asians.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Esophagogastric Junction; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Staging; Palliative Care; Stomach Neoplasms; Survival Analysis; Treatment Outcome | 2003 |
Irinotecan and paclitaxel in metastatic adenocarcinoma of the esophagus and gastric cardia.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Esophageal Neoplasms; Female; Humans; Irinotecan; Male; Middle Aged; Paclitaxel; Stomach Neoplasms | 2003 |
Stimulation of CD40 inhibits Fas- or chemotherapy-mediated apoptosis and increases cell motility in human gastric carcinoma cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Carcinoma; CD40 Antigens; CD40 Ligand; Cell Division; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Survival; fas Receptor; Flow Cytometry; Humans; Stomach Neoplasms; Tetrazolium Salts; Thiazoles | 2003 |
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinoma, Signet Ring Cell; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Krukenberg Tumor; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Ovarian Neoplasms; Ovariectomy; Stomach Neoplasms | 2003 |
[A case of advanced cancer with liver metastasis and paraaortic lymph node metastasis responding remarkably to combination chemotherapy of low-dose CDDP, 5-FU and CPT-11].
Topics: Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Cisplatin; Drug Administration Schedule; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Stomach Neoplasms | 2003 |
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Ovarian Neoplasms; Prognosis; Quality of Life; Skin Neoplasms; Stomach Neoplasms | 2003 |
Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Cisplatin; Female; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Postoperative Complications; Stomach Neoplasms; Treatment Outcome | 2003 |
[Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Quality of Life; Radiotherapy Dosage; Stomach Neoplasms; Tegafur | 2003 |
Unresectable alpha fetoprotein-producing gastric cancer successfully treated with irinotecan and mitomycin C after S-1 failure.
Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Mitomycin; Oxonic Acid; Pyridines; Radiography; Stomach Neoplasms; Tegafur; Treatment Failure | 2004 |
[Successful downstaging by a low-dose, fractional administration of irinotecan hydrochloride (CPT-11) in combination with cisplatin in peritoneal lavage cytology positive, 5-fluorouracil refractory advanced gastric cancer patients].
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; Carcinoma, Signet Ring Cell; Cholecystectomy; Cisplatin; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Middle Aged; Neoplasms, Multiple Primary; Splenectomy; Stomach Neoplasms | 2004 |
A preliminary study of preoperative chemotherapy combining irinotecan and cisplatin in patients with gastric cancer with unresectable para-aortic lymph node metastases.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Gastrectomy; Humans; Irinotecan; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Preoperative Care; Stomach Neoplasms | 2004 |
Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Male; Metallothionein; Middle Aged; Oligonucleotide Array Sequence Analysis; Stomach Neoplasms | 2004 |
[A case of TS-1 resistant recurrent gastric cancer responding to TS-1 +CPT-11 combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Irinotecan; Male; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2004 |
Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorouracil; Humans; Irinotecan; NF-kappa B; Stomach Neoplasms | 2004 |
Treatment issues in pediatric gastric adenocarcinoma.
Topics: Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Signet Ring Cell; Catheter Ablation; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gastrectomy; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Irinotecan; Liver Neoplasms; Lymph Node Excision; Neoplasm Recurrence, Local; Neoplastic Syndromes, Hereditary; Pancreatectomy; Prognosis; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Remission Induction; Reoperation; Splenectomy; Stomach Neoplasms; Taxoids | 2004 |
[CPT-11 hepatic arterial infusion chemotherapy for metastatic liver tumor from gastric cancer].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Humans; Infusions, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Stomach Neoplasms | 2004 |
[A case of liver metastatic recurrence of gastric cancer effectively treated by combined chemotherapy of CPT-11 and CDDP].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Female; Gastrectomy; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Quality of Life; Stomach Neoplasms | 2004 |
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine | 2005 |
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Adenocarcinoma; Amphiregulin; Antineoplastic Agents; Camptothecin; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Metalloproteases; Phosphorylation; Quinazolines; Reactive Oxygen Species; Stomach Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |
[Short-term effects of chemotherapy with combination of hydroxycamptothecine and oxaliplatin in the treatment of advanced digestive tract cancers].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Diarrhea; Female; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2004 |
[Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationships to expressions of P-glycoprotein and glutathione S transferase-pi].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Nucleus; Cisplatin; Cytoplasm; Doxorubicin; Drug Resistance, Neoplasm; Female; Fluorouracil; Glutathione S-Transferase pi; Humans; Male; Middle Aged; Mitomycin; Stomach Neoplasms; Tumor Cells, Cultured | 2005 |
[Complete response of recurrent gastric cancer to chemotherapy with TS-1 and CPT-11--a case report].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oxonic Acid; Pyridines; Remission Induction; Stomach Neoplasms; Tegafur | 2005 |
[A case of peritoneal dissemination of gastric cancer successfully treated by irinotecan combined with cisplatin].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Quality of Life; Remission Induction; Stomach Neoplasms | 2005 |
[A case report of bowel obstruction due to peritonitis carcinomatosa using combined administration with CPT-11 and CDDP].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Gastrectomy; Humans; Intestinal Obstruction; Irinotecan; Male; Middle Aged; Peritoneal Neoplasms; Peritonitis; Stomach Neoplasms | 2005 |
Darpp-32: a novel antiapoptotic gene in upper gastrointestinal carcinomas.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Dopamine and cAMP-Regulated Phosphoprotein 32; Esophageal Neoplasms; Gene Dosage; Humans; Intracellular Membranes; Membrane Potentials; Mitochondria; Nerve Tissue Proteins; Phosphoproteins; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Stomach Neoplasms; Tumor Suppressor Protein p53; Up-Regulation | 2005 |
Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Humans; Inhibitory Concentration 50; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms | 2005 |
[Assessment of immunotoxicity of irinotecan determined by the novel method, by which productivity of TNF-alpha from whole blood is stimulated by lipopolysaccharide].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Biomarkers; Blood; Camptothecin; Colonic Neoplasms; Female; Humans; Immunologic Tests; Infusions, Intravenous; Irinotecan; Lipopolysaccharides; Male; Middle Aged; Monocytes; Stomach Neoplasms; Tumor Necrosis Factor-alpha | 2005 |
[A case of advanced gastric cancer with lymphangitis carcinomatosa after operation of Krukenberg tumor treated by TS-1 plus CPT-11 as third-line chemotherapy].
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Krukenberg Tumor; Lymphangitis; Ovarian Neoplasms; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of advanced gastric cancer with obstructive jaundice that responded to TS-1/CPT-11 combination therapy after percutaneous transhepatic cholangio drainage].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biliary Tract; Camptothecin; Combined Modality Therapy; Drainage; Drug Administration Schedule; Drug Combinations; Gastroscopy; Humans; Irinotecan; Jaundice, Obstructive; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Tegafur | 2005 |
[A case of small cell carcinoma of the stomach].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Rupture, Spontaneous; Stomach Neoplasms; Stomach Rupture | 2005 |
Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with irinotecan and cisplatin.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Drug Administration Schedule; Female; Glutathione S-Transferase pi; Humans; Irinotecan; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2005 |
[Chemotherapy for patients with advanced/recurrent gastric cancer and the practice at our institute].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Pyridines; Stomach Neoplasms; Taxoids; Tegafur | 2005 |
[CPT-11-induced diarrhea treated with indisetron hydrochloride--a case report].
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Camptothecin; Diarrhea; Drug Administration Schedule; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Pyrazoles; Quality of Life; Stomach Neoplasms | 2005 |
Transarterial chemoembolization with degradable starch microspheres, irinotecan, and mitomycin-C in patients with liver metastases.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoembolization, Therapeutic; Colonic Neoplasms; Disease Progression; Hepatic Artery; Humans; Injections, Intra-Arterial; Irinotecan; Liver Neoplasms; Male; Microspheres; Middle Aged; Mitomycin; Rectal Neoplasms; Remission Induction; Starch; Stomach Neoplasms; Topoisomerase I Inhibitors | 2006 |
[A case of gastric cancer with peritoneal dissemination who achieved five-year survival by successive treatments with TS-1 alone and in combination with other drugs].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Male; Mitomycin; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Pyridines; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Floxuridine; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Paclitaxel; Pyridines; Stomach Neoplasms; Tegafur | 2006 |
[The present state and future of home care for gastric cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Forecasting; Home Care Services, Hospital-Based; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Parenteral Nutrition, Home; Pyridines; Quality of Life; Stomach Neoplasms; Tegafur | 2006 |
[A case of gastric cancer presenting with obstructive jaundice and responding to biweekly CPT-11 and CDDP combination administration].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drainage; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Jaundice, Obstructive; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Stomach Neoplasms | 2006 |
[Blood supply of pulmonary metastases and its clinical significance].
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bronchial Arteries; Camptothecin; Chemoembolization, Therapeutic; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Iodized Oil; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Radiography; Remission Induction; Stomach Neoplasms; Young Adult | 2006 |
[A case of inoperable gastric small cell carcinoma effectively treated by chemotherapy and radiotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Cranial Irradiation; Drug Administration Schedule; Drug Combinations; Etoposide; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2006 |
Histone deacetylase inhibitor, trichostatin A, increases the chemosensitivity of anticancer drugs in gastric cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluorouracil; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival; Female; Fluorouracil; Humans; Irinotecan; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Stomach Neoplasms; Survival Rate | 2006 |
A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination.
Topics: Animals; Camptothecin; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Female; Humans; Image Processing, Computer-Assisted; Irinotecan; Luciferases; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneal Neoplasms; Photons; Stomach Neoplasms; Transfection | 2006 |
Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Feasibility Studies; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2006 |
[A case of non-curatively resected gastric cancer successfully treated over 17 months with TS-1 and irinotecan combination therapy].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Female; Gastrectomy; Humans; Irinotecan; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nausea; Neutropenia; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].
Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardia; Cisplatin; Drug Administration Schedule; Drug Combinations; Fluorouracil; Humans; Irinotecan; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2006 |
[A case of advanced gastric cancer with long-term survival treated by chemotherapy and surgical cytoreduction].
Topics: Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Oxonic Acid; Quality of Life; Stomach Neoplasms; Survivors; Tegafur | 2006 |
[In vitro chemo-sensitivity MTT assay guided intraperitoneal chemotherapy for malignant ascites].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Ascites; Camptothecin; Cell Survival; Colorectal Neoplasms; Docetaxel; Female; Humans; Injections, Intraperitoneal; Kaplan-Meier Estimate; Male; Middle Aged; Pancreatic Neoplasms; Stomach Neoplasms; Taxoids; Tumor Cells, Cultured | 2006 |
[A recurrent endocrine cell cancer of the stomach showing almost complete remission after chemotherapy for 1 year].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carcinoma, Small Cell; Cisplatin; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Remission Induction; Stomach Neoplasms | 2006 |
A case report--The marked response to gemcitabine combined with irinotecan and low-dose cisplatin chemotherapy for advanced gastric cancer with multiple liver metastases.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; Irinotecan; Liver Neoplasms; Male; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2006 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
[A case of stage IV gastric cancer treated sequentially for over two years by TS-1, paclitaxel, and CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Male; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survivors; Tegafur | 2007 |
Retrospective evaluation of sequential outpatient chemotherapy for advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Combinations; Female; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survival Analysis; Tegafur | 2007 |
[A case of advanced gastric cancer with obstructive jaundice due to multiple liver metastasis successfully treated with the following combination therapy of CPT-11 and cisplatin after combination therapy of paclitaxel and TS-1].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Irinotecan; Jaundice, Obstructive; Liver Neoplasms; Male; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Survivors; Tegafur | 2007 |
[A case report of gastric small cell carcinoma with long survival time by adjuvant chemotherapy--reports of chemotherapy regimens for gastric small cell carcinoma].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Routes; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Oxonic Acid; Stomach Neoplasms; Survivors; Tegafur | 2007 |
[A case of TS-1 resistant recurrent gastric cancer with lung metastasis responding to TS-1 and irinotecan combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Drug Resistance, Neoplasm; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Oxonic Acid; Pancreas; Splenectomy; Stomach Neoplasms; Tegafur | 2007 |
Establishment and characterization of an IGSK-2 cell line derived from ascitic fluid of recurrent hCG and somatostatin secreted adenocarcinoma of the stomach.
Topics: Adenocarcinoma, Mucinous; Adult; Animals; Antigens, Tumor-Associated, Carbohydrate; Ascitic Fluid; Biomarkers, Tumor; Camptothecin; Carcinoembryonic Antigen; Cell Line, Tumor; Chorionic Gonadotropin; Cisplatin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Immunohistochemistry; Irinotecan; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Somatostatin; Stomach Neoplasms | 2007 |
Sensitivity to CPT-11 and platinum derivatives of stage I/II node-negative breast, lung, and gastric cancer with occult neoplastic cells in lymph node sinuses.
Topics: Antineoplastic Agents, Phytogenic; bcl-2-Associated X Protein; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; DNA-Binding Proteins; Endonucleases; Humans; Immunoenzyme Techniques; Irinotecan; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Polymerase Chain Reaction; Stomach Neoplasms; Topoisomerase I Inhibitors | 2007 |
[Evaluation of combination chemotherapy with 5-FU, CDDP and CPT-11 for human gastric carcinoma transplanted into nude mice - comparative study of in vivo chemosensitivity test].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Irinotecan; Mice; Mice, Nude; Neoplasm Transplantation; Stomach Neoplasms | 2007 |
[Therapeutic strategy for type 4 gastric cancer from the clinical oncologist standpoint].
Topics: Adenocarcinoma, Scirrhous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug Combinations; Female; Fluorouracil; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Prognosis; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[Irinotecan+cisplatin and irradiation are effective for brain metastases of gastric cancer--two case reports].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gastrectomy; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Quality of Life; Radiosurgery; Radiotherapy Dosage; Remission Induction; Splenectomy; Stomach Neoplasms | 2007 |
[Complete remission of hepatic metastasis of gastric cancer with CPT-11].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Liver Neoplasms; Male; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
Capecitabine and irinotecan in advanced gastric cancer.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Irinotecan; Stomach Neoplasms; Treatment Outcome | 2007 |
[Effects of hydroxycamptothecin and teniposide on proliferation and apoptosis of gastric cancer cell line BGC-823].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Humans; Stomach Neoplasms; Teniposide; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors | 2007 |
[A case of advanced gastric cancer responding remarkably to neo-adjuvant combination chemotherapy using CPT-11 plus S-1].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Humans; Irinotecan; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Invasiveness; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of unresectable gastric cancer complicated by serious pyloric stenosis in which S-1 administration after gastrojejunostomy proved effective].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Combined Modality Therapy; Drug Administration Schedule; Drug Combinations; Gastric Bypass; Humans; Irinotecan; Male; Middle Aged; Oxonic Acid; Paclitaxel; Pyloric Antrum; Pyloric Stenosis; Stomach Neoplasms; Tegafur | 2007 |
[Results of chemotherapy using new anti-cancer drugs since S-1 for advanced or recurrent gastric cancer in our institute].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Drug Combinations; Female; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Neoplasm Staging; Oxonic Acid; Paclitaxel; Quality of Life; Stomach Neoplasms; Survival Rate; Tegafur | 2007 |
[A case of cytology-positive, stage IV gastric cancer, alive with no recurrence for 4 years, curatively treated with combination chemotherapy using S-1, CPT-11 and subsequent total gastrectomy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Camptothecin; Drug Administration Schedule; Drug Combinations; Gastrectomy; Humans; Irinotecan; Lymph Node Excision; Male; Neoplasm Staging; Oxonic Acid; Remission Induction; Stomach Neoplasms; Tegafur | 2007 |
Bi-weekly irinotecan hydrochloride and cisplatin as a second-line chemotherapy for patients with advanced gastric cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2007 |
[Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Therapy; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Immunosuppressive Agents; Irinotecan; Male; Methotrexate; Middle Aged; Oxonic Acid; Paclitaxel; Stomach Neoplasms; Tegafur | 2007 |
The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; ErbB Receptors; Female; Fluorodeoxyglucose F18; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Positron-Emission Tomography; Predictive Value of Tests; Prospective Studies; Radiopharmaceuticals; Remission Induction; Stomach Neoplasms; Treatment Outcome | 2007 |
[Three successful cases with CPT-11 + CDDP chemotherapy where S-1 failed to respond to recurrent gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Cisplatin; Drug Combinations; Female; Follow-Up Studies; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Oxonic Acid; Recurrence; Salvage Therapy; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of unresectable gastric cancer successfully treated with combination chemotherapy of S-1 + CPT-11].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Gastroscopy; Humans; Irinotecan; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Tegafur; Tomography, X-Ray Computed | 2007 |
[A case of S-1 resistant multiple lung metastases after curative total gastrectomy for gastric cancer successfully treated by S-1 combined with CPT-11 as the third-line chemotherapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic Antigen; Drug Combinations; Drug Resistance, Neoplasm; Female; Gastrectomy; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Stomach Neoplasms; Tegafur; Time Factors; Tomography, X-Ray Computed | 2007 |
Impacts of excision repair cross-complementing gene 1 (ERCC1), dihydropyrimidine dehydrogenase, and epidermal growth factor receptor on the outcomes of patients with advanced gastric cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camptothecin; Chemotherapy, Adjuvant; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Disease Progression; DNA Primers; DNA-Binding Proteins; Drug Combinations; Endonucleases; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Oxonic Acid; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Survival Rate; Tegafur | 2008 |
[Clinical experience of second-line chemotherapy with S-1/CPT-11 for highly advanced gastric cancer].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Response Relationship, Drug; Drug Combinations; Gastroscopy; Humans; Irinotecan; Male; Neoplasm Staging; Oxonic Acid; Stomach Neoplasms; Survival Rate; Tegafur; Tomography Scanners, X-Ray Computed | 2008 |
CPT21, a novel compound with anti-proliferative effect against gastric cancer cell SGC7901.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Caspases; Cell Line, Tumor; Cell Proliferation; DNA Breaks, Double-Stranded; DNA Replication; DNA Topoisomerases, Type I; Dose-Response Relationship, Drug; Gene Expression Regulation; Humans; Inhibitory Concentration 50; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Mice, Nude; Stomach Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2008 |
Frequent overexpression of Aurora Kinase A in upper gastrointestinal adenocarcinomas correlates with potent antiapoptotic functions.
Topics: Adenocarcinoma; Apoptosis; Aurora Kinase A; Aurora Kinases; Biomarkers, Tumor; Blotting, Western; Camptothecin; Coloring Agents; Cytochromes c; Enzyme Inhibitors; Esophageal Neoplasms; Flow Cytometry; Gene Expression Regulation, Enzymologic; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Luciferases; Luminescent Agents; Polymerase Chain Reaction; Protein Array Analysis; Protein Serine-Threonine Kinases; Stomach Neoplasms; Tetrazolium Salts; Thiazoles; Tumor Suppressor Protein p53 | 2008 |
Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Retrospective Studies; Salvage Therapy; Stomach Neoplasms; Survival Analysis | 2008 |
Tolerance and efficacy of adjuvant chemoradiotherapy with FOLFIRI in adenocarcinoma of stomach and GI junction.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant; Esophagogastric Junction; Fluorouracil; Humans; Leucovorin; Middle Aged; Stomach Neoplasms | 2008 |
[A case of advanced gastric cancer with peritoneal metastasis successfully treated over 19 months with postoperative chemotherapy after non-curative surgery].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Combinations; Female; Fluorouracil; Gastrectomy; Humans; Irinotecan; Methotrexate; Oxonic Acid; Paclitaxel; Peritoneal Neoplasms; Stomach Neoplasms; Tegafur | 2008 |
Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin).
Topics: Animals; Antineoplastic Agents, Phytogenic; Camptothecin; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance; Humans; Irinotecan; Male; Mice; Mice, Nude; Stomach Neoplasms; Transplantation, Heterologous; Tumor Cells, Cultured | 1995 |
The multidrug resistance-associated protein gene confers drug resistance in human gastric and colon cancers.
Topics: Antineoplastic Agents; Camptothecin; Cisplatin; Colonic Neoplasms; Doxorubicin; Etoposide; Genes, MDR; Humans; Irinotecan; Mitomycin; Polymerase Chain Reaction; RNA, Messenger; Stomach Neoplasms; Tumor Cells, Cultured; Verapamil; Vincristine | 1996 |
Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Camptothecin; Cell Cycle; Cell Survival; DNA Topoisomerases, Type II; Doxorubicin; Drug Interactions; Etoposide; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lung Neoplasms; Paclitaxel; Polymerase Chain Reaction; Rhodamines; Stomach Neoplasms; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured; Vincristine | 1997 |
Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Camptothecin; Colonic Neoplasms; Humans; Irinotecan; Kidney Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Stomach Neoplasms; Subrenal Capsule Assay; Tumor Cells, Cultured | 1998 |
[A case of advanced gastric cancer successfully treated by neoadjuvant chemotherapy with CPT-11, CDDP and 5-FU].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Fluorouracil; Gastrectomy; Humans; Irinotecan; Lymphatic Metastasis; Male; Neoadjuvant Therapy; Remission Induction; Stomach Neoplasms | 1999 |
Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Humans; Male; Mice; Mice, Inbred BALB C; Microfilament Proteins; Muscle Proteins; Proto-Oncogene Proteins c-bcl-2; Stomach Neoplasms; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
[Three cases of multiple liver metastases of gastric cancer responding to tegafur/low-dose CDDP/CPT-11 combination chemotherapy].
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Liver Neoplasms; Male; Stomach Neoplasms; Tegafur | 1999 |
[A case of advanced gastric cancer with lung and liver metastasis responding remarkably to combination chemotherapy with CDDP and CPT-11].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug Administration Schedule; Humans; Infusions, Intravenous; Irinotecan; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Stomach Neoplasms | 2000 |
Tumor markers CEA, CA19-9 and CA125 in monitoring of response to systemic chemotherapy in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Camptothecin; Carcinoembryonic Antigen; Cisplatin; Female; Fluorouracil; Humans; Irinotecan; Male; Methotrexate; Middle Aged; Predictive Value of Tests; Prognosis; Sensitivity and Specificity; Stomach Neoplasms; Survival Rate | 1999 |
[Experimental study on CPT-11 intraperitoneal chemotherapy--metabolism of CPT-11 in malignant ascites].
Topics: Antineoplastic Agents, Phytogenic; Ascites; Camptothecin; Humans; Infusions, Parenteral; Irinotecan; Peritoneal Neoplasms; Stomach Neoplasms | 2000 |
Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Division; Dose-Response Relationship, Drug; Enzyme Inhibitors; Genes, p53; Humans; Stomach Neoplasms; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
[A case of AFP-producing gastric cancer responding to low-dose CPT-11 and low-dose cisplatin combination chemotherapy].
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Middle Aged; Stomach Neoplasms | 2001 |
[Chemotherapy by combination of low-dose CPT-11 and PSK in an elderly man with liver metastasis from gastric cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Schedule; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Male; Proteoglycans; Stomach Neoplasms | 2001 |
Preliminary study of fortnightly irinotecan hydrochloride plus cisplatin therapy in patients with advanced gastric and colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal Neoplasms; Drug Administration Schedule; Female; Humans; Irinotecan; Male; Middle Aged; Stomach Neoplasms; Survival Rate; Treatment Outcome | 2001 |
[A case of advanced gastric cancer treated with neoadjuvant chemotherapy of low-dose CPT-11 + CDDP].
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Humans; Irinotecan; Male; Middle Aged; Neoadjuvant Therapy; Stomach Neoplasms | 2001 |
[Pharmacokinetic study of the intraperitoneal administration of CPT-11 for patients with peritoneal seedings of gastric and colonic cancers].
Topics: Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Colonic Neoplasms; Female; Humans; Injections, Intraperitoneal; Irinotecan; Male; Middle Aged; Neoplasm Seeding; Peritoneal Neoplasms; Stomach Neoplasms | 2001 |
Combination chemotherapy of irinotecan plus cisplatin for advanced gastric cancer: efficacy and feasibility in clinical practice.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Female; Humans; Irinotecan; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2001 |
[Globalization of anti-cancer therapies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; Carboplatin; Cisplatin; Colorectal Neoplasms; Etoposide; Female; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Stomach Neoplasms | 2002 |
Cancer of the gastrointestinal tract. Chemotherapy.
Topics: Antineoplastic Agents; Camptothecin; Carmustine; Cyclohexanes; Cyclophosphamide; Drug Therapy, Combination; Fluorometholone; Fluorouracil; Humans; Hydroxyurea; Mitomycins; Nitrosourea Compounds; Remission, Spontaneous; Stomach Neoplasms; Streptonigrin; Time Factors | 1974 |